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1. Abbreviations 
BMI    Body mass index 
BP    Blood pressure 
CI    Confidence interval 
CV    Cardiovascular 
FATCOR   FAT associated CardiOvasculaR dysfunction 
GLS    Global longitudinal strain 
LA    Left atrial 
LV    Left ventricular 
OR    Odds ratio 




2. Scientific environment 
This research project was undertaken in the Bergen Hypertension and Cardiac 
Dynamics group at the Department of Clinical Science, University of Bergen, and 
supported by the Norwegian National Advisory Unit on Women’s Health, Oslo 
University Hospital, Oslo, Norway.  
 The Bergen Hypertension and Cardiac Dynamics group is headed by 
Professor Eva Gerdts. Professor Knut Matre, associate professor Mai Tone 
Lønnebakken, post-doctoral fellow Helga Midtbø, 4 PhD-fellows, 2 research medical 
students. Several consultants in cardiology employed at the Department of Heart 
Disease, Haukeland University Hospital, also work in the group. Our group focuses 
on non-invasive cardiac imaging methods in clinical and experimental studies. The 
Bergen Hypertension and Cardiac Dynamics group is responsible for the 
Echocardiography Research Laboratory, which is a state-of-the-art core laboratory 
for echocardiographic image analysis.  
The Bergen Hypertension and Cardiac Dynamics group has a large network of 
collaborators, extending both nationally and internationally. Collaborators include 
Professor Giovanni de Simone (Hypertension Research Centre, Federico II 
University, Naples, Italy), Professor Richard B. Devereux (Weill Medical College, 
Cornell University, New York, USA), Professor Vera Regitz-Zagrosek (Institute for 
Gender Medicine, Charité University, Berlin, Germany), Professor Sverre E. 
Kjeldsen (University of Oslo, Oslo, Norway), Professor Geir Christensen (University 
of Oslo, Oslo, Norway), Professor Maja-Lisa Løchen (The Arctic University of 
Norway, Tromsø, Norway), Professor Kirsti Ytrehus (The Arctic University of 
Norway, Tromsø, Norway). 
The Norwegian National Advisory Unit on Women’s Health is headed by 
Professor Siri Vangen and was founded in 2006. The primary aim of this advisory 
unit is to do research and disseminate knowledge about women’s health in a lifetime 
perspective. The research group includes 4 researchers, 9 post-doctoral fellows and 7 
PhD-fellows. The unit’s main focus is on reproductive health, but also includes 
research into cancers that affect women and cardiovascular health.  
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5. Abstract  
Background: Fitness may influence cardiovascular (CV) health in obesity. We 
explored the impact of fitness on CV risk factors and prevalent subclinical CV 
disease in overweight and obese women and men without known CV disease. 
Materials and methods: Clinical and echocardiographic data from the FAT 
associated CardiOvasculaR dysfunction (FATCOR) study was used for analyses of 
CV risk factors and subclinical CV disease in relation to fitness. Fitness was 
determined by sex- and age-adjusted peak oxygen uptake on a maximal treadmill test.  
Results: Hypertension, metabolic syndrome and diabetes were highly and equally 
prevalent in fit and unfit groups (all p>0.05) (Study 1). In >40% of cases, prevalent 
hypertension and diabetes were diagnosed in-study. Being fit was characterized by 
lower waist circumference, non-obesity, non-smoking and higher muscle mass (all 
p<0.05). Women had more subclinical cardiac disease (77% vs. 62%) and left atrial 
(LA) dilatation (74% vs. 56%) than men, while men had more abnormal left 
ventricular (LV) geometry (30% vs. 21%, all p<0.05) (Study 2). Female sex more 
than doubled the risk of prevalent subclinical cardiac disease (95% confidence 
interval [CI] 1.48-3.22) and LA dilatation (95% CI 1.67-3.49), while male sex 
doubled the risk of abnormal LV geometry (95% CI 1.30-3.01) (all p<0.05). Fitness 
was not associated with prevalent subclinical CV disease (p>0.05). Mean global 
longitudinal strain (GLS) was similar between fit and unfit groups within overweight 
and obese groups (both p>0.05), while low GLS was more prevalent in the unfit vs. 
the fit obese group (30% vs. 10%, p<0.05) (Study 3). In obesity, but not overweight, 
fitness was associated with higher GLS (more negative value) (odds ratio 0.87 [95% 
CI 0.79-0.99, p<0.05), independent of confounders.  
Conclusion: The prevalences of major CV risk factors and subclinical cardiac 
disease were high and uninfluenced by fitness. Despite this, fitness in obesity was 
associated with improved myocardial function. Our findings indicate that women are 
at particular risk of subclinical cardiac disease, and that fitness alone cannot 
compensate for the harmful effects of increased body mass index. Furthermore, our 
results demonstrate the benefit of a thorough assessment of CV risk in such subjects.  
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6. Introduction 
6.1 Obesity as a global health problem 
Nowadays, cardiovascular (CV) disease is estimated to be responsible for more than 
30% of annual deaths, making CV disease the leading cause of death in the world.1 
At the same time, nearly 2 billion of the world’s adult population is overweight, and 
more than 1/3 of these have developed obesity.2, 3 This obesity epidemic is a driving 
force for the development of hypertension, and a major risk factor for developing CV 
disease.4, 5 In fact, in 2015 approximately 4 million deaths globally were attributed to 
high body mass index (BMI), and more than 2/3 of these deaths were caused by CV 
disease.6 Interestingly, almost 40% of reported deaths occurred in overweight 
subjects,6 highlighting that overweight is not a benign condition.  
Similar to numerous other countries, the obesity epidemic is evident also in 
Norway. Currently, the average Norwegian adult is overweight, and normal-weight is 
found in a minority, estimated present in 40% of women and in only 25% of men.7 
The Norwegian Institute of Public Health reports that, in middle-aged subjects, 
obesity is present in 20% of women and 25% of men.7 Compared to the global 
prevalence of obesity, which is estimated to be 15% in women and 11% in men,2 the 
prevalence of obesity is higher among middle-aged adults in Norway.7 Taken 
together, these data suggest that most Norwegian adults are at increased risk of 
subclinical and clinical CV disease from overweight and obesity alone. 
To combat the obesity pandemic and the large burden of CV disease, physical 
activity is recommended for the prevention and treatment of both.8, 9 Epidemiological 
studies have demonstrated that increased physical activity and improved fitness are 
independently associated with reduced CV morbidity and mortality.10-14 For instance, 
a recent prospective cohort study of healthy Norwegians showed that higher peak 
oxygen uptake reduced the risk of fatal and non-fatal coronary heart disease by 
16%.12 However, as demonstrated in another recent cohort study, being physically 
active could not overcome negative impact of obesity on risk of myocardial 
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infarction.13 Thus, taken together, the impact of fitness on CV health in obese 
women and men without known CV disease remains unclear.  
6.2 Clustering of cardiovascular risk factors in obesity 
When overweight or obesity is present, the likelihood of co-presence of other potent 
CV risk factors increases.15 The obesity pandemic is considered the driver of the 
observed increase in incidence of hypertension and type 2 diabetes in the world.15, 16  
Globally, hypertension is the most important modifiable CV risk factor and a 
large proportion of the burden of CV disease is attributable to hypertension.17 It is 
well documented that the prevalence of hypertension increases in parallel with 
increasing BMI.18, 19 Interestingly, the effect of increasing BMI on blood pressure 
(BP) differs between women and men, and also between non-obese and obese 
subjects.19 For a similar increase in BMI in obesity, women experience a larger 
increase in BP than men.20 Additionally, the BP increase is larger in obese women 
compared to non-obese women, while the BP increase associated with weight gain is 
independent of initial BMI in men.21 
The impact of fitness on hypertension in overweight and obesity is not fully 
understood. In a Swedish cohort study including more than 1.5 million male military 
conscripts, both increased BMI and poor fitness on maximal exercise testing were 
independently associated with a higher risk of hypertension later in life.22 A 
prospective cohort study of Finnish adults tested the single and joint effects of BMI 
and self-reported physical activity on risk of hypertension in women and men, and 
found that both lower BMI and higher physical activity were independently 
associated with a lower risk of developing hypertension regardless of sex.23 They also 
showed that the positive impact of physical activity on incident hypertension was 
present in both women and men with increased BMI.23 In an American population-
based study of 950 women and men, no associations between prevalent hypertension 
and physical activity or fitness were identified.24 These previous studies, however, 
based identification of physical activity and fitness on self-reports and submaximal 
exercise testing.23, 24  
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 Overweight and obesity are strongly associated with diabetes.25 When 
diabetes is present, the risk of CV diseases like stroke and coronary heart disease 
increases, and the increase in risk is higher in women than in men.26, 27 Additionally, 
CV morbidity and mortality is increased in subjects with diabetes and poor fitness, 
independent of abdominal adiposity.28 Also, a previous population-based study of 
obese subjects without known CV disease or diabetes, found moderate physical 
activity to be associated with reduced risk of incident diabetes.29 Taken together, 
these findings suggests that fitness may contribute in reducing the risk of incident 
diabetes in obese women and men, as well as reducing CV complications in subjects 
with established diabetes. 
 Metabolic syndrome describes the clustering of CV risk factors like obesity, 
hypertension, diabetes and atherogenic dyslipidemia.30 The prevalence of metabolic 
syndrome sharply increases with increasing BMI,30-32 and the presence of metabolic 
syndrome is associated double risk of CV diseases like myocardial infarction and 
stroke, as well as CV mortality.33 Several meta-analyses have also found that the 
increase in CV risk associated with metabolic syndrome is higher in women than in 
men.33-35 Cross-sectional population-based studies from Finland have demonstrated 
that lower self-reported physical activity and poorer peak oxygen uptake on maximal 
exercise testing is associated with higher prevalence of metabolic syndrome in older 
subjects and middle-aged men.36, 37 Interestingly, emerging evidence from a recently 
published study offers an alternative and plausible explanation for the cross-sectional 
associations between metabolic syndrome and fitness.38 In that study, which was an 
exercise intervention study of women and men with metabolic syndrome, exercise-
induced weight loss was associated with improvements in the metabolic syndrome Z-
score, a continuous metabolic syndrome risk score, but not with increase in peak 
oxygen uptake.38 This suggests that the positive impact of fitness on prevalent 
metabolic syndrome may well be attributable to weight loss. Taken together, there is 
a need for further studies on the impact of fitness, assessed by directly measured peak 
oxygen uptake from maximal exercise testing, on the prevalence and clustering of 
major CV risk factors in subjects with increased BMI.  
 17 
6.3 Subclinical cardiovascular disease 
Following the current paradigm, subclinical CV diseases usually develop following 
progressive accumulation of CV risk factors like hypertension and obesity, and 
precede the development of clinical CV diseases like myocardial infarction, heart 
failure and atrial fibrillation.9 Therefore, timely identification of CV risk factors and 
appropriate risk factor management are considered key in both primary and 
secondary prevention of CV disease.9 In line with this, identification of subclinical 
CV disease in hypertensive patients may more accurately identify high risk subjects 
than the degree of BP elevation.39  
Subclinical CV disease is defined as structural or functional changes in the 
heart or in the arteries. Common types of subclinical cardiac disease includes left 
atrial (LA) dilatation, abnormal left ventricular (LV) geometry or reduced global 
longitudinal strain (GLS). The term abnormal LV geometry includes distinct 
phenotypes of LV geometry, defined based on the presence of concentric geometry 
and/or LV hypertrophy.40 Subclinical cardiac disease in subject with increased BMI 
may be induced by both the hemodynamic and non-hemodynamic effects of obesity 
and influenced by co-presence of other CV risk factors like diabetes or 
hypertension.41 In fact, increased BMI is an independent risk factor for both 
subclinical and clinical CV disease, even after adjustment for other CV risk factors.5, 
15, 21, 42, 43 Other mechanisms explaining the association of increased BMI with 
subclinical CV disease are related to proinflammatory and pro-fibrotic 
neuroendocrine activation in visceral fat leading to chronic low-grade CV 
inflammation41 as well as peri- and myocardial fat accumulation infiltrating the 
myocardium, resulting in myocardial steatosis.44 Studies have shown that the 
susceptibility both to develop26, 27, 45-47 and respond to treatment48, 49 of subclinical 
cardiac damage may differ by sex. For instance, studies have demonstrated that being 
female is associated with prevalent LV hypertrophy, particularly when obesity and 
hypertension are co-present.21, 50 As obesity and CV disease represent significant 
burdens for both women and men, this thesis seeks to highlight sex-differences in this 
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context. Thus, there is a particular need for further data on sex differences in 
obesity-associated subclinical cardiac disease.  
Subclinical cardiac disease is often asymptomatic, but the presence of 
subclinical cardiac disease is associated with very high risk for subsequent clinical 
CV disease events.51-53 For example, LA dilatation is a predictor of atrial fibrillation, 
stroke and death.53-55 Further, the presence of LV hypertrophy is associated with 
increased CV morbidity and mortality, including increased risk of sudden cardiac 
death.56, 57 Also, even a modest reduction in LV systolic function is a strong predictor 
of CV events and death.58  
Subclinical arterial diseases like arterial remodeling and increased arterial 
stiffness are particularly common among hypertensive subjects and may be assessed 
by carotid ultrasound and carotid-femoral pulse-wave velocity.46, 59 However, the 
impact of obesity on subclinical arterial disease is less clear. Some studies suggest a 
direct association between obesity and subclinical arterial disease, while others 
indicate that this association is in fact mediated through obesity-associated metabolic 
abnormalities.46, 60, 61 Nevertheless, prevalent subclinical arterial disease is associated 
with higher risk of CV morbidity and mortality.62, 63 Thus, early detection and 
appropriate treatment of subclinical CV disease is of utmost importance in order to 
prevent serious adverse events. However, less is known about the impact of fitness on 
subclinical CV disease in overweight and obese women and men without known CV 
disease.    
6.4 Myocardial function in obesity 
Previous studies have demonstrated that obesity is associated with reduced LV 
systolic function independent of LV mass, both when measured as LV ejection 
fraction and midwall shortening.42, 64 Traditionally, LV ejection fraction is the most 
used measure of LV systolic function. The prognostic value of LV ejection fraction 
has been established in a variety of study populations,40, 65, 66 and LV ejection fraction 
guides decision-making in clinical practice, ranging from device implantation in heart 
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failure to use of cardiotoxic cancer treatment.67, 68 However, LV ejection 
fraction may remain normal despite a considerable reduction in myocardial  
contractility.69, 70 In assessment of subclinical cardiac disease, more sophisticated 
measures are now used to allow earlier detection of myocardial dysfunction.71 In 
particular, use of speckle tracking echocardiography allows for assessment of LV 
systolic function by GLS, which in turns enables the detection of reduced LV systolic 
function at a time when LV ejection fraction is still within normal range.70, 72-75 
Additionally, GLS is an independent and powerful predictor of CV morbidity and 
mortality.72, 76 The presence of overweight and obesity has consistently been 
associated with reduced LV systolic function when assessed by GLS, but 
inconsistently with reduced LV ejection fraction.73-75, 77 However, the impact of 
fitness on GLS in obesity has previously only been assessed in small studies, and 
with contrasting findings.78, 79 In a study of 9 obese adolescents, fitness was 
associated with higher GLS,79 while no association was found in a study of 39 young 
females with abdominal adiposity.78 Thus, further data is needed on the impact of 




7. Hypothesis and aims 
7.1 Hypothesis 
We hypothesized that fitness was associated with lower prevalences of CV risk 
factors and subclinical CV disease in overweight and obese women and men without 
known clinical CV disease 
7.2 Aims 
Main aim 
To determine the impact of fitness on prevalences of CV risk factors and subclinical 




Study 1:  To assess the association of fitness with prevalence of CV risk factors 
and subclinical arterial disease in overweight and obese women and 
men without known clinical CV disease 
 
Study 2: To assess the association of fitness with subclinical cardiac disease in 
overweight and obese women and men without known clinical CV 
disease 
 
Study 3: To assess the effect of fitness on LV myocardial function in overweight 
and obese women and men without known clinical CV disease 
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8. Methods 
8.1 Study population 
This thesis was based upon the participants in the FAT associated CardiOvasculaR 
dysfunction (FATCOR) study. The FATCOR study is cross-sectional in design, and 
was performed at the Department of Heart Disease, Haukeland University Hospital, 
Bergen, Norway. Data collection was initiated in October 2009 and finalized March 
2017. AlfaHelse A/S, a collaborating general practice center specializing in the 
management of overweight and obesity, was responsible for recruitment of 
participants. In total, 620 women and men were included. Of these, 2 participants 
later withdrew consent, and subsequently, all data from these were excluded from 
analyses. Thus, 618 participants were included in the final data set (Figure 1). 
Inclusion criteria were age 30-65 years and a BMI >27 kg/m2. Exclusion criteria were 
previous myocardial infarction, gastrointestinal disorder, severe psychiatric illness or 
the inability to understand Norwegian language. Written, informed consent was 
obtained from all participants prior to inclusion. The FATCOR study was approved 
by the Western Norway Regional Ethics Committee (approval number 3.2008.1946) 














Figure 1: Flow chart of FATCOR study population that was included in 
Study 1-3 
 
8.2 Cardiovascular risk assessment 
After inclusion, an initial physical examination at the general practitioner center was 
performed. This was followed by a rigorous CV evaluation program at the 
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. 
8.2.1 Overweight and obesity 
By inclusion criteria, all participants were either overweight or obese. The criteria 
from the World Health Organization were used to distinguish between overweight, 
defined as a BMI ≥ 25.0 kg/m2, and obesity, defined as a BMI ≥ 30.0 kg/m2.2 
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8.2.2 Clinic and ambulatory blood pressure 
Clinic BP was measured, as recommended in the guidelines, by the general 
practitioner using a standardized procedure and an Omron M4 sphygmomanometer 
(Omron Healthcare Co. Ltd., Hoofdorp, Netherlands.17 A cuff appropriate for each 
participants’ arm circumference was used, and the measurement was performed with 
the participant in the sitting position. After 5 minutes of rest, the BP was measured in 
triplets with 1-minute intervals. The average of the 2 last measurements was taken as 
the clinic BP. The BP was considered elevated if systolic BP ≥140 mmHg and/or 
diastolic BP ≥ 90 mmHg.17 Pulse pressure was calculated as the difference between 
the systolic BP and the diastolic BP, and mean BP was calculated as diastolic BP plus 
1/3 of the pulse pressure. 
The 24-hour blood pressure (24-h BP) monitoring was performed with a 
Diasys Integra II recorder (Novacor, Cedex, France), in accordance with guidelines.17 
Each participant was fitted with a cuff of appropriate size for their individual arm 
circumference on the non-dominant arm. The device was programmed to measure the 
BP twice per hour during the night and three times per hour during the day, which 
added up to 78 measurements in 24 hours. The 24-h BP was repeated if <70% of the 
measurements were valid. The participants were carefully instructed to keep their arm 
still during cuff inflation, to adhere to their daily routines, but to avoid hard physical 
exercise. The 24-h BP was considered elevated if 24-h systolic BP ≥130 mmHg 
and/or 24-h diastolic BP ≥80 mmHg.17  
By combining the results from clinic BP and 24-h BP, four distinct BP 










Figure 2: BP phenotypes as determined by clinic BP and 24-h BP in combination. 
 
SBP, systolic blood pressure. DBP, diastolic blood pressure. 
 
We considered hypertension to be present if participants used antihypertensive drugs 
or if elevated 24-h BP (systolic BP ≥130 mmHg and/or diastolic BP ≥80 mmHg) was 
found. We used the mean systolic BP during daytime and night-time from the 24-h 
BP monitoring to determine dipping status. If mean systolic BP increased from 
daytime to night-time, reverse dipping was present. If there was <10% reduction in 
mean systolic BP from daytime to night-time, the participant was classified as a non-
dipper. 
8.2.3 Diabetes  
All participants had their fasting blood glucose and HbA1c measured after an 
overnight fast followed by venous blood sampling. In addition, all non-diabetic 
participants were subjected to a standardized 75 gram oral glucose tolerance test in 
order to reveal diabetes not identified by fasting blood glucose or HbA1c. This was 
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followed by blood samples to measure blood glucose two hours after the 
glucose solution was ingested.  
Diabetes in the participants was diagnosed using the criteria from the 
American Diabetes Association.80 If fasting blood glucose was ≥7 mmol/L and/or 
HbA1c ≥6.5% (equal to 48 mmol/mol) and/or the 2-hour blood glucose was 
≥11.1mmol/L after the 75-gram oral glucose tolerance test, diabetes was diagnosed.80 
When calculating the total prevalence of diabetes in the study population, participants 
with known diabetes and participants using antidiabetic medication were also 
included. 
 Impaired fasting blood glucose was defined as fasting blood glucose 5.6-6.9 
mmol/L.80 Impaired glucose tolerance was present if the 2-hour blood glucose 
following the oral glucose tolerance test was 7.8-11.0 mmol/L.80  
8.2.4 Metabolic syndrome 
Metabolic syndrome was diagnosed using the criteria from the American Heart 
Association/National Heart, Lung and Blood Institute.30 Following these criteria, 
metabolic syndrome was considered present if 3 out of 5 required criteria were met in 
the individual participants. The following criteria were applied: 1) Increased waist 
circumference (≥88 cm in women, ≥102 cm in men), 2) elevated triglycerides ≥1.7 
mmol/L, 3) low high-density lipoprotein cholesterol (<1.3 mmol/L in women, <1.03 
mmol/L in men), 4) systolic BP ≥130 mmHg and/or diastolic BP ≥85 mmHg and/or 
use of antihypertensive medication, or 5) high fasting blood glucose ≥5.6 mmol/L 
and/or use of antidiabetic medication.30 
8.2.5 Body composition analysis 
Body composition analysis was performed by bioelectrical impedance analysis 
(Tanita TBF-300A, Tanita Corporation of America, Arlington Heights, USA). The 
device was tetrapolar and measured bioelectrical impedance by a foot-foot system. 
The bioelectrical impedance analysis estimated fat mass (kg), fat percentage (%), 
muscle mass (%) and fat-free mass (kg). 
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8.2.6 Self-reported health 
All participants completed a standardized questionnaire on self-reported health. The 
questionnaire included questions about the participants’ general health, medical 
history, time spent on physical activity per week and use of both prescription and 
non-prescription medication.  
8.2.7 Fasting venous blood samples 
After an overnight fast, fasting venous blood samples were drawn. The samples were 
analyzed at validated laboratories using standardized methods and evaluated using 
standard reference values. Analyses included, but were not limited to, measurement 
of hemoglobin, glycosylated hemoglobin, fasting blood glucose, creatinine, total 
cholesterol, high-density lipoprotein cholesterol and triglycerides. In order to 
calculate estimated glomerular filtration rate, we used the Chronic Kidney Disease 
Epidemiology Collaboration equation.81 
8.3 Assessment of subclinical arterial disease 
8.3.1 Aortic stiffness 
Arterial stiffness was assessed from carotid-femoral pulse wave velocity measured by 
applanation tonometry (SphygmoCor, Atcor Medical, Sydney, West Ryde, Australia) 
in order to evaluate aortic stiffness. The measurement was performed after the 
participants had rested for 15 minutes in the supine position. Transcutaneous 
recordings of pressure pulse waveforms were obtained from the right common carotid 
artery and the femoral arteries with simultaneous recording of electrocardiogram in 
order to synchronize carotid- and femoral pulse wave times (Figure 3). The distance 
between the carotid recording site and the sternal notch (the proximal distance) and 
the distance between the sternal notch and the femoral recording site (the distal 
distance) were carefully measured. The carotid-femoral pulse wave velocity was 
calculated as the distal distance minus the proximal distance, divided by the transit 
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time, automatically adjusted for mean BP and reported in m/s. As 
recommended, increased aortic stiffness was considered present if a carotid-femoral  
pulse wave velocity >10 m/s was found.17, 82 
 





8.3.2 Carotid intima-media thickness 
Carotid ultrasound (Philips iE33, Philips Healthcare, Best, Netherlands) was used for 
measuring carotid intima-media thickness. The maximal carotid intima-media 
thickness in end-diastole was measured following a comprehensive protocol 
including the near and far wall of the common and internal carotid arteries and the 
carotid bulb on both the left and right side (Figure 4). In accordance with the 
guidelines, a mean carotid intima-media thickness >0.9 mm was considered 
increased, and a focal carotid intima-media thickness ≥1.5 mm was taken as a carotid 
plaque.17 
 
Figure 4: Ultrasound image of the right common carotid artery with bifurcation. The 
distance the blue lines represent the intima-media thickness. 
 
 
Courtesy of Halvor Øygarden, MD PhD. 
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8.4 Assessment of subclinical cardiac disease 
8.4.1 Echocardiographic imaging and analysis 
A GE Vivid E9 scanner (GE Vingmed Ultrasound, Horten, Norway) (n=549) or a 
Phillips iE33 (Philips Healthcare, Best, Netherlands) (n=32) scanner was used for 
echocardiographic examinations. The examination followed a standardized imaging 
protocol. Image analysis of conventional measures was performed at the 
Echocardiography Core Laboratory at the University of Bergen, Bergen, Norway, on 
workstations with Image Arena Software version 4.1 (Tomtec Imaging Systems 
GmbH, Unterschleissheim, Germany), and was done in accordance with the joint 
guidelines from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging on quantitative echocardiography.40 Junior 
investigators performed the initial image analysis, and as is recommended for clinical 
trials, all images were subsequently proofread by a single expert reader (EG).83 This 
ensured highly reproducible measurements, as previously published from our 
Echocardiography Core Laboratory.84  
EchoPac BT 202 software (GE Vingmed Ultrasound, Horten, Norway) was 
used for analysis of speckle tracking strain. Thus, analysis of GLS could only be 
performed in patients where echocardiography was performed by a GE 
echocardiograph (Figure 1). The analyses were performed by a single investigator 
(NP), followed by proof-reading by one highly experienced reader (SS). Peak systolic 
longitudinal strain was assessed in 17 segments of the LV using 4-, 3- and 2-chamber 
apical views. Automated function imaging with an adequate frame rate (50-70 fps) 
was used, and the analysis was performed as recommended by the vendor (GE). End-
diastole was defined from the electrocardiogram and end-systole was defined from 
aortic valve closure from a pulsed wave Doppler recording. The endocardial border 
was then tracked automatically with manual corrections. The quality of the automatic 
tracking was assessed visually after software processing, and the segment was 
excluded if the tracking was poor. GLS was calculated as the average of peak systolic 
longitudinal strain in 17 segments of the LV.  
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Figure 5: Segmental representation of peak systolic GLS from 3 apical 
views of the LV. 
 
 
8.4.2 Left atrial dilatation 
LA systolic volume was calculated by the area-length method combining apical 2- 
and 4-chamber views. If LA systolic volume indexed for height2 ≥16.5 ml/m2 in 
women and ≥18.5 ml/m2 in men, LA dilatation was considered present. These sex-
specific cut-off values represent the upper 95th percentile of LA volume index in 
healthy European populations.85 
8.4.3 Left ventricular geometry 
Parasternal long-axis 2-dimensional views were used to measure the wall thicknesses 
and cavity diameters of the LV. Devereux’s validated formula was used for 
calculating LV mass,86 and the LV mass was then indexed for height2.7. LV 
hypertrophy was considered present if LV mass index exceeded the prognostically 
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validated cut-off values of >46.7 g/m2.7 in women and >49.2 g/m2.7 in men.45 
Concentric LV geometry was considered present if LV relative wall thickness 
exceeded the cut-off value of ≥0.43, calculated from end-diastolic measurements as 2 
x posterior wall thickness/LV internal diameter.40 
LV geometric phenotype was determined by combing LV relative wall 
thickness and LV mass index in the individual participant (Figure 6).40 Normal 
geometry was present if both LV mass index and LV relative wall thickness were 
normal. Eccentric LV hypertrophy was considered present if LV mass index was 
increased, but LV relative wall thickness was normal. Concentric remodeling was 
present if LV mass index was normal and LV relative wall thickness increased. 
Concentric LV hypertrophy was present if both LV mass index and LV relative wall 
thickness were increased. Concentric LV geometry was considered present if either 
concentric remodeling or concentric LV hypertrophy was found in the individual 
participant. 
 
Figure 6: LV geometric phenotypes 
 
RWT, relative wall thickness; LV, left ventricular. 
 32 
8.4.4 Left ventricular function 
LV systolic function was assessed at the endocardial level by LV ejection fraction, 
which was calculated using modified Simpson’s rule (biplane method of discs).40 As 
recommended by the current guidelines, the LV ejection fraction was defined as low 
if <54% in women and if <52% in men.40  
The LV systolic myocardial function was assessed by peak systolic GLS. GLS 
is reported as a negative value as the LV shortens in systole. Thus, if the LV shortens 
less, as in reduced systolic function, the GLS will be a less negative value (closer to 
zero). Correspondingly, a higher GLS is represented by a more negative value. Based 
upon data from a healthy European population, investigated by using the same vendor 
and software as used in the present project, GLS was considered abnormal if >-18.5% 
in women and if >-16.9 in men.87  
8.5 Exercise testing and fitness 
8.5.1 Exercise testing 
In order to test cardiorespiratory fitness, ergospirometry was performed on a treadmill 
(Schiller CS-200, Schiller AG, Baar, Switzerland) using a standardized protocol 
(Chronotropic Assessment Exercise Protocol) particularly suited for overweight and 
obese subjects. The protocol is incremental both in speed and elevation, but has a 
longer warm up period than other commonly used ergospirometry protocols. Peak 
oxygen uptake and respiratory exchange ratio was measured by a breath-to-breath 
technique. In order to avoid air leakage and to facilitate accurate measurement of 
peak oxygen uptake, the participants were fitted with a correctly sized face mask, 
covering both mouth and nose. For continuous heart rate and heart rhythm 
monitoring, the participants were equipped with electrodes for a 12-lead 
electrocardiogram. Unless contraindications to further testing arose during the test 
(such as severe chest pain, severe dyspnea, significant ST-segment depression or -
elevation as sign of severe ischemia or ventricular tachycardia detected by 
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electrocardiogram), all participants were instructed to continue testing until 
complete exhaustion. Chest pain caused premature abortion of testing in 5 subjects.  
As all of these reached a high respiratory exchange ratio (at least 1.2), indicating 
sufficient effort, and therefore remained included in the analyses.  
8.5.2 Classification of fitnessDirectly measured peak oxygen uptake under a 
maximal ergospirometry test, the gold standard for exercise testing, was used for 
evaluation of fitness in the FATCOR study. As peak oxygen uptake varies with sex 
and age, a sex- and age-adjusted classification system of cardiorespiratory fitness was 
used.88 Using this classification system, the participants were grouped into very poor, 
poor, fair, average, good, very good and excellent cardiorespiratory fitness 88 We 
defined the participants as fit if they reached at least a good level of fitness, and as 
unfit if a lower level of fitness was achieved (Table 1). 
 
Table 1: Sex-and age-adjusted cut-off values for peak oxygen uptake 
 
 
Age range (years) 
Cut-off peak oxygen 
uptake for fit women 
(ml/kg/min) 
Cut-off peak oxygen 
uptake for fit men 
(ml/kg/min) 
30-34  NA >49.6 
35-39  >38.2 >51.4 
40-44  >37.2 >46.7 
45-49  >34.2 >43.3 
50-54  >33.8 >40.2 
55-59 >30.8 >39.0 
60-65 >27.8 >38.6 
NA, not applicable. 
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8.6 Statistics 
The Statistical Package for Social Sciences software versions 23-25 (IBM, Armonk, 
New York, USA) was used for both data management and statistical analysis. All 
data were plotted manually by a technician, and then proof-read by a second person 
to ensure accuracy. Continuous variables were presented as mean±standard deviation, 
and categorical variables as percentages.  
When comparing two groups, Student’s T-test was used for continuous 
variables and Chi-square test for categorical variables. When comparing four groups, 
a general linear model with Scheffe’s or Sidak’s post hoc test was used for 
comparison of categorical variables, and one-way analysis of variance with Sidak’s 
post hoc test was used for comparison of continuous variables.  
Uni- and multivariable logistic regression analyses were used to identify 
covariables of fitness (study 1), LA dilatation/concentric LV geometry/abnormal LV 
geometry/subclinical cardiac disease (study 2) and fitness in overweight and obese 
groups separately (study 3). Only variables with a p-value <0.01 in univariable 
logistic regression analyses were included in multivariable logistic regression 
analyses. The results from these analyses were reported as odds ratio (OR)  
with their 95% confidence intervals (CI).  
 The intraclass correlation coefficient was calculated to assess the interobserver 
variability of GLS measurements. The threshold for statistical significance was set to 
p<0.05 for all analyses. 
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9. Summary of results 
9.1 Study 1  
Halland H, Lønnebakken MT, Saeed S, Midtbø H, Cramariuc D, Gerdts E. Does 
fitness improve the cardiovascular risk profile in obese subjects? Nutr Metab 
Cardiovasc Dis. 2017;27:518-24. 
The aim of study 1 was to assess the association of fitness with prevalence of CV risk 
factors and subclinical arterial disease in overweight and obese women and men 
without known clinical CV disease. At the time of study, data collection was still on-
going, and the 491 participants who had completed study examinations including 
ergospirometry testing per November 2015 were included in the study. These 
participants were on average 48 years old, 60% were women and 28% were classified 
as fit. 
Despite lower 24-h systolic BP and mean BP in the fit group (both p<0.05), the 
prevalences of hypertension (63% in unfit vs. 58% in fit) did not differ between the 
groups (p>0.05). Similarly, the prevalences of different BP categories did not differ 
between fit and unfit groups (all p>0.05). There were no significant differences in 
average fasting blood glucose or the prevalences of impaired fasting glucose, 
impaired glucose tolerance or diabetes between the fit and unfit groups (all p>0.05). 
The prevalence of MetS was high (45%), and did not differ between the groups 
(p>0.05). When studying the five qualifying criteria for MetS, there were no 
significant differences in the prevalence of these between the fit and unfit groups. 
Prevalence of subclinical arterial disease was unexpectedly low, and did not differ 
between fit and unfit groups. The prevalence of carotid plaques was higher in men 
than women (26% vs. 17%, p<0.05). 
Fitness was characterized by absence of obesity, lower waist circumference, 
non-smoking, lower fat mass, lower daytime mean BP, higher self-reported physical 
activity and higher muscle mass (all p<0.05) in univariable logistic regression 
analyses. After adjusting for confounders in multivariable logistic regression analysis, 
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fitness was independently associated with having a lower waist 
circumference, absence of obesity, non-smoking and a higher muscle mass (all 
p<0.05).  
9.2 Study 2 
Halland H, Lønnebakken MT, Pristaj N, Saeed S, Midtbø H, Einarsen E, Gerdts E. 
Sex differences in subclinical cardiac disease in overweight and obesity (the 
FATCOR study). Nutr Metab Cardiovasc Dis. 2018;28:1054-60. 
The aim of study 2 was to assess the impact of fitness on prevalence of subclinical 
cardiac disease in overweight and obese women and men without known clinical CV 
disease. Subclinical cardiac disease was defined as presence of LA dilatation and/or 
abnormal LV geometry. Readable echocardiograms were obtained in 581 
participants, and these were included in the study. These participants were on average 
48 years old and 60 % were women.   
No association of fitness with prevalent subclinical cardiac disease was found 
(70% in unfit group vs. 72% in fit group, p>0.05) (Figure 7). However, interesting 
sex differences in prevalences and types of subclinical cardiac disease were identified 
during data analysis. Helped by reviewers, we re-focused the paper. LA dilatation 
was highly prevalent in the total study population (67%), and more common in 
women than men (74% vs. 56%, p<0.05). The prevalences of LA dilatation, abnormal 
LV geometry and concentric LV geometry did not differ between fit and unfit groups 
(all p>0.05). In multivariable logistic regression analysis in the total study population, 
female sex was independently associated with a 2-fold (OR 2.42 [95% CI 1.67-3.49) 
higher prevalence of LA dilatation independent of a significant association with 
higher pulse pressure (OR 1.02 per 1 mmHg [95% CI 1.00-1.04].  
On average every fourth participant had abnormal LV geometry, and this was 
more common in men than women (30% vs. 21%, p<0.05). Women and men had 
similar prevalences of eccentric LV hypertrophy and concentric LV remodeling 
(p>0.05), but men had more concentric LV hypertrophy (p<0.05). In the total study 
population, male sex was associated with a near 2-fold (OR 1.81 [95% CI 1.19-2.78], 
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p<0.05) higher risk of having abnormal LV geometry in multivariable 
logistic regression analysis, independent of higher pulse pressure (OR 1.02 per 1 
mmHg [95% CI 1.00-1.04]), higher BMI (OR 1.12 per kg/m2 [95% CI 1.06-1.17])  
and higher age (OR 1.04 per year [95% CI 1.02-1.07]) (all p<0.05). 
Grouping any presence of subclinical cardiac disease (dilated LA and 
abnormal LV geometry together), the majority (71%) of the participants had 
subclinical cardiac disease, and this was even more prevalent in women compared to 
men (77% vs. 62%, p<0.05). In the total study population, female sex was associated 
with a 2-fold (OR 2.19 [95% CI 1.48-3.22]) higher risk of any subclinical cardiac 
disease independent higher pulse pressure (OR 1.03 per 1 mmHg [95% CI 1.01-
1.05]) and higher BMI (OR 1.06 per 1 kg/m2 [95% CI 1.01-1.12]) (all p<0.05) in 
multivariable logistic regression analysis. In sex-specific, multivariable logistic 
analysis, presence of any subclinical cardiac disease was independently associated 
with higher pulse pressure in women (OR 1.06 per 1 mmHg [95% CI 1.00-1.16]), 
while in men, higher 24-h pulse pressure (OR 1.04 per 1 mmHg [95% CI 1.00-1.17]) 
and higher fat free mass (OR 1.04 per 1 kg [95% CI 1.00-1.08]) were both 
independent covariables of prevalent subclinical cardiac disease (all p<0.05).  
 













Abnormal LV geometry LA dilatation Any subclinical cardiac
disease
Fit Unfit
All p>0.05 between groups
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9.3 Study 3 
Halland H, Matre K, Midtbø H, Saaed S, Pristaj N, Einarsen E, Lønnebakken MT, 
Gerdts E. Effect of fitness on left ventricular systolic myocardial function in 
overweight and obesity (the FATCOR study). Submitted to Nutr Metab Cardiovasc 
Dis. 
The aim of study 3 was to assess the effect of fitness on LV myocardial function in 
the FATCOR population. Data on both ergospirometry and speckle tracking 
echocardiography was required for this study, and this was available in 469 of the 
participants (76% of the total FATCOR population). These participants were on 
average 47 years old, 60% were women and mean BMI was 32.0 kg/m2. Within the 
overweight and obese groups, the prevalences of hypertension, diabetes and 
metabolic syndrome did not differ between fit and unfit subgroups of participants. 
 GLS and LV ejection fraction did not differ between fit and unfit groups 
among overweight subjects (both p>0.05). Among obese subjects, LV ejection 
fraction was higher and abnormal GLS was less common in the fit group (both 
p<0.05), although mean GLS was similar and within normal range both in fit and 
unfit groups (p>0.05). The obese unfit group had lower (less negative) GLS than the 
overweight unfit group (p<0.05).  
 In univariable logistic regression analyses in the overweight group, no 
significant associations were found between fitness and measures of LV systolic 
function. In multivariable logistic regression analysis, fitness in the overweight group 
was independently associated with lower serum triglycerides (OR 0.50 per 1 mmol/L 
[95% CI 0.30-0.84]) and lower body fat percentage (OR 0.96 per 1 % [95% CI 0.92-
1.00]) (both p<0.05). 
 In univariable logistic regression analyses in the obese group, fitness was 
associated with higher GLS, LV ejection fraction, pulse pressure and LV mass index 
and with lower body fat percentage (all p<0.05). After adjusting for confounders in 
multivariable logistic regression analysis, the association between fitness and higher 
(more negative) GLS (OR 0.87 per % [95% CI 0.77-0.99], p<0.05) remained 
statistically significant.  
 39 
Reproducibility of peak systolic GLS measurements was evaluated in  
26 randomly selected patients with excellent intraclass correlation coefficient (0.96 





This PhD-project studied the impact of cardiorespiratory fitness on CV risk factors 
and prevalent subclinical CV disease in overweight and obese women and men 
without known clinical CV disease participating in the cross-sectional FATCOR 
study. A number of clinically important findings were identified in the project: 
Firstly, we demonstrated that CV risk factors are highly prevalent in overweight and 
obesity, and to the same extent in fit and unfit subjects. The presence of CV risk 
factors was frequently unknown to the participants, emphasizing the importance of a 
thorough CV risk assessment in overweight and obese subjects. Secondly, we showed 
that subclinical cardiac disease was present in the majority of the participants, and 
that obesity-related subclinical cardiac disease disproportionally affected women, 
while subclinical arterial disease was found in a minority, and more common in men. 
Further, prevalent subclinical CV disease was not influenced by fitness. Taken 
together these findings suggest that use of echocardiography ideally should be 
performed routinely in subjects with increased BMI to detect individuals at high or 
very high risk of CV events reflected by the presence of subclinical cardiac disease. 
Thirdly, we demonstrated that although fitness did not impact the prevalence of 
subclinical cardiac disease, fitness was associated with better LV systolic myocardial 
function in obese subjects, but not in overweight subjects. Thus, our findings 
highlight the negative impact of overweight and obesity on cardiac health and 
emphasize the importance of a thorough evaluation of CV risk factors. Optimally, 
such evaluation in overweight and obese subjects should include ambulatory BP 
monitoring, oral glucose tolerance testing and advanced echocardiography to 
optimize CV disease prevention regardless of fitness status.  
10.1 Fitness and cardiovascular risk in obesity  
The total burden of CV risk factors in the FATCOR population was high. By design, 
the FATCOR study included subjects at increased risk for clustering of 
cardiometabolic risk factors, and subsequently, for the development of subclinical 
 41 
and clinical CV disease.4, 5, 15 As reported by the Norwegian Institute of 
Public Health, only 25% of Norwegian men and 40% of Norwegian women are 
estimated to have a normal BMI.7 Considering that most Norwegians adults are either 
overweight or obese,7 the FATCOR cohort can therefore provide valuable insights 
relevant for the average Norwegian adult.  
More than 2/3 of the FATCOR participants were unfit, and therefore at 
increased risk of CV disease and death according to previous reports.10, 12-14 The 
association between physical activity and CV disease and mortality was first 
documented in 1953 by Morris et al.14 In that study sedentary bus drivers had an 
increased incidence of coronary heart disease and death compared to the more active 
conductors on double-decker buses.14 Later studies have confirmed this association in 
larger samples, with more precise measures of physical activity and fitness, and for 
several CV outcomes.10, 12, 13 In a prospective study, more than 9700 American men 
underwent maximal exercise testing twice to investigate the relationship between 
changes in fitness and CV- and all-cause mortality.10 They found that the persistently 
fit men had the lowest risk of all-cause- and CV death, while the highest risk was 
found in the persistently unfit men.10 In addition, they found that, compared to their 
persistently unfit counterparts, men that progressed from being unfit to fit, had a 44% 
and 52% lower risk for age-adjusted all-cause and CV mortality, respectively.10 
Regrettably, the study did not include enough women to report results for women, 
and despite their use of maximal exercise testing, their definition of fitness relied on 
exercise duration, rather than directly measured peak oxygen uptake.10  
Similarly, an inverse and independent association between fitness and 
mortality was demonstrated in randomly selected sample of 1294 Finnish men in the 
population-based Kuopio Ischaemic Heart Disease study.89 In fit men, the risk of all-
cause and CV mortality was reduced regardless of whether fitness was quantified as 
exercise duration or directly measured peak oxygen uptake from maximal exercise 
testing.89 Furthermore, the association between higher fitness and lower risk of fatal 
and non-fatal coronary heart disease was preserved in both women and men in a fit, 
and on average overweight and middle-aged Norwegian population, with a low 
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prevalence of clustering of CV risk factors.12 The latter study, based upon the 
Nord-Trøndelag Health Study, could however not show that higher fitness reduced  
all-cause mortality.12 Taken together, these studies provide convincing arguments for 
the positive impact of fitness on risk of clinical CV morbidity and mortality. 
The relationship between fitness and CV health in obesity has been  
investigated in several studies, and the fat-but-fit paradigm arose following 
publications from the Aerobics Center Longitudinal Study.90, 91 In short, these studies 
showed that fit obese men had lower risk of CV mortality than unfit overweight or 
unfit normal-weight men, suggesting that fitness could eliminate or neutralize the 
negative impact of obesity.90, 91 In the Nurses’ Health study, which explored the joint 
effects of BMI and physical activity on mortality, they found that the physically 
active obese women had a lower risk of CV- and all-cause mortality than inactive 
obese women.92 They did not, however, find that a high level of physical activity was 
able to fully compensate for the increased risk of CV- and all-cause mortality 
associated with obesity, nor could leanness compensate for negative effects of low 
physical activity.92 Other large cohorts have also found that physical activity can 
attenuate, but not eliminate the increased risk associated with obesity.93-95 A recent 
publication from the population-based Tromsø Study, found that higher level of self-
reported physical activity reduced, but did not eliminate, the increased risk of having 
a myocardial infarction associated with increased BMI.13 Together, these results 
indicate that CV risk in obesity may be reduced by physical activity and fitness, but 
the fact that these study results relied on self-reported physical activity rather than 
exercise testing, which is known to be more strongly associated with all-cause 
mortality, represents a weakness in study design that may have impacted the results.96 
The caveats of using self-reported physical activity were highlighted in a large 
prospective cohort study comparing the impact of self-reported physical activity and 
fitness on all-cause mortality in women and men.96 In that study they found that 
fitness quantified by exercise testing was associated with reduced mortality in both 
women and men, and interestingly, that there was no association between mortality 
and self-reported physical activity in women.96  
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In the FATCOR project we found that fit subjects had a lower 
prevalence of obesity and lower waist circumference, reflecting less abdominal 
obesity, but despite this, we could not find that fitness was associated with a lower 
prevalence of major CV risk factors like hypertension, diabetes or metabolic 
syndrome. This is in contradiction to the cross-sectional FINRISK-study, which 
found that fitness had a positive impact on CV risk factor profile regardless of 
abdominal adiposity.97 Two important differences in population characteristics and 
study methods may account for the divergent findings. Compared to the FATCOR 
cohort, the participants in the FINRISK study were leaner with an average BMI <27 
kg/m2 compared to the average BMI of 32 kg/m2 in the FATCOR cohort. 
Furthermore, in FINRISK fitness was estimated from a non-exercise aerobic fitness 
test, in contrast to being directly measured from a maximal exercise test in the 
FATCOR-study.97 Our findings indicate that, in FATCOR subjects, obesity had a 
more powerful impact on CV risk factor profile than fitness.  
10.1.1 Hypertension in obesity 
The overall prevalence of hypertension the FATCOR cohort was 60%, which is much 
higher than the prevalence reported for general population of similar age in Norway 
in the Nord-Trøndelag Health Study.98 In that population based study 30% of women 
and 50% of men had hypertension.98 In comparison, in study 2, we demonstrated that 
53% of women and 72% of men had hypertension. Thus, higher prevalence of 
hypertension was observed both among FATCOR women and men compared to 
general Norwegian population, but hypertension remained more common in men, 
reflecting the known sex difference in prevalent hypertension with age.99 Given the 
established association between obesity and hypertension, the high prevalence of 
hypertension in the FATCOR cohort is likely a consequence of increased BMI.19 In 
addition, the FATCOR participants were examined with 24-h BP, and it is possible 
that this more sensitive method enabled a more accurate identification of 
hypertension.100 However, the low prevalences of white-coat hypertension and 
masked hypertension in the FATCOR population suggests that the use of 24-h BP 
alone cannot account for the high prevalence of hypertension in the present study 
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population. Another possible contributing factor to the high prevalence of 
hypertension in our cohort, is that we had some publicity from a major local 
newspaper during the recruitment period of the participants. The newspaper article 
focused on obesity-associated CV risk, and this may have motivated obese subjects 
with other known CV risk factors like hypertension to participate. 
Although the fit group in study 1 had lower 24-h systolic BP, the prevalence of 
antihypertensive treatment, hypertension and hypertension subtypes did not differ 
between fit and unfit groups. We expanded these findings in study 3 by 
demonstrating that the 24-h systolic BP and prevalences of hypertension also did  
not differ by fitness within the overweight and obese groups, but rather by absence or 
presence of obesity. These findings are in agreement with reports from the National 
Health and Nutrition Survey, in which no association between hypertension and peak 
oxygen uptake or self-reported physical activity was found.24  However, in that study 
peak oxygen uptake was estimated from submaximal exercise testing. Thus, the 
present study adds to previous knowledge by showing even that when the gold 
standard of direct measurement of peak oxygen uptake during maximal exercise 
testing was utilized, fitness still did not impact hypertension prevalence. Taken 
together, these results suggest that fitness alone is unable to attenuate the negative 
impact of excess body fat on BP. However, a prospective study design with serial 
assessment of fitness and associated changes in CV risk factor burden and body 
composition would be needed to confirm this hypothesis.  
 Another important finding in study 1 was that 46% of all cases of hypertension 
in the FATCOR study were identified as a result of the diagnostic work-up in the 
study. At the same time, less than 60% of subjects with known hypertension used 
antihypertensive treatment. These findings suggest that hypertension is 
underdiagnosed and undertreated in overweight and obese subjects. It is, however, 
possible that the relatively low prevalence of antihypertensive drug treatment in our 
cohort could reflect that participants were attempting to implement lifestyle change 
with weight loss prior to initiating antihypertensive drug treatment. The current 
guidelines for management of arterial hypertension suggests that this can be an 
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adequate strategy in some subjects, in particular in those with mild 
hypertension and few other CV risk factors, reflecting mild-moderately increased  
over-all risk for clinical CV disease. However, ultimately drug treatment is necessary 
in most subjects with hypertension, and weight loss is often unsustainable in the long 
term.39 Thus, antihypertensive treatment should probably have been initiated in the 
vast majority of the hypertensive FATCOR participants.39 Previously, the 
Framingham Heart Study showed that a 5% increase in body weight was associated 
with a 20-30% higher incidence of hypertension,101 and the Harvard Male Alumni 
study found that a weight gain of 25 pounds (~ 12.5 kg) was associated with a 60% 
increase in hypertension incidence.102 The presence of higher BMI and hypertension 
has further clinical implications, as illustrated in a pooled analysis of 97 prospective 
cohort studies of 1.8 million adults without previous stroke or coronary heart 
disease.103 That meta-analysis showed that for each 5-unit increase in BMI, the risk of 
stroke increases by 18% and the risk of coronary heart disease increases by 27%.103 
Interestingly, they found that 1/3 of the increased risk of coronary heart disease and 
2/3 of the increased risk stroke associated with increased BMI, was mediated by 
BP.103 Altogether, our results and current knowledge emphasize that vigilance is 
required in detection and treatment of hypertension in overweight and obese subjects.  
10.1.2 Diabetes  
Diabetes was present in 12% of the total study population, which is about 3 times 
higher compared to the general population in Norway, estimated by the Norwegian 
Institute of Public Health based on data from the Norwegian Prescription Database.104 
As the entire FATCOR cohort is overweight and obese, the higher prevalence may 
well reflect the known association between increased BMI and higher incidence and 
prevalence of type 2 diabetes.25 The risk of clinical CV disease is increased in 
diabetes, and furthermore, the impact of diabetes on risk of CV disease differs by 
sex.26, 27 In a meta-analysis of more than 800,000 individuals, women with diabetes 
had a nearly 3-fold higher risk of coronary heart disease compared to women without 
diabetes.26 In men with diabetes, the risk was 2-fold compared to men free from 
diabetes.26 Furthermore, the evidence suggests that when diabetes is present, women 
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have more than 40% higher risk of coronary heart disease than men.26 
Similarly, the presence of diabetes considerably increases the risk of stroke, and more 
so in women than men.27 
Previous studies have indicated that fitness can attenuate the increased risk of 
diabetes associated with overweight and obesity.20, 105 For example, a prospective 
study of >6000 American women suggested that, in overweight and obesity, unfit 
women had a 40% higher risk of incident diabetes than fit women.105 When compared 
to lean women, in which risk of incident diabetes remained unchanged by fitness, the 
risk of incident diabetes was 2-fold in overweight and obese women.105 Similarly, a 
prospective study of >3,500 American men, showed that fit obese men had nearly 
50% lower risk of incident diabetes compared to unfit obese men, but the risk was 
still 3-fold compared to normal-weight fit men.20 Although these studies defined 
fitness from exercise duration of a maximal exercise test, and not from directly 
measured peak oxygen uptake, their results indicate that fitness can attenuate, but not 
eliminate, the increased risk of diabetes associated with increased BMI.20, 105  In 
contrast, in the current FATCOR population, the prevalence of diabetes did not differ 
by fitness, sex or presence of obesity.  
Of note, 42% of all cases of diabetes in the FATCOR study were diagnosed 
through the study work up, and additionally 1/5 had impaired fasting blood glucose, 
indicating particularly high risk of developing diabetes.106 When the prevalences of 
diabetes and impaired fasting blood glucose were grouped, there were no differences 
between overweight and obese subjects. Again, as indicated above, it is possible that 
our study attracted a subgroup of individuals with increased BMI that already were 
aware of having additional CV risk factors, and this may influenced our results. 
However, our findings show that the presence of diabetes in overweight and obese 
subjects is largely unknown to both patient and physician, and that fitness may not 
protect from diabetes in all populations.  
10.1.3 Metabolic syndrome 
Metabolic syndrome was highly prevalent in the FATCOR cohort, and present in 
45% of the participants. In a population based cohort of Norwegians of similar age,  
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prevalent metabolic syndrome was reported in 28% of women and in 22% of 
men.107 Given the known association between increased BMI and metabolic 
syndrome, the observed discrepancy in prevalence is likely caused by more 
abdominal obesity and hypertension in our study population.30-32  As shown in the 
present project, the prevalence of metabolic syndrome did not differ by fitness or sex, 
but rather by obesity. This is in contrast to several other cross-sectional studies that 
have identified an inverse association between metabolic syndrome and fitness.36, 37, 
108 In a recently published study, subjects with metabolic syndrome were randomized 
to a systematic exercise program or to retain their habitual, sedentary lifestyle.38 The 
effect on a composite score for metabolic syndrome components was analyzed, and 
the study concluded that improvement of metabolic syndrome components was 
caused by the weight loss associated with the exercise program, and not by the 
achieved increase in peak oxygen uptake,38 which may explain the findings in the 
FATCOR study. 
10.2 Subclinical cardiovascular disease 
10.2.1 Subclinical arterial disease 
While subclinical cardiac disease was highly prevalent in the FATCOR cohort, 
subclinical arterial disease was not despite the high prevalence of hypertension. Our 
findings contrast previous observations in the Campania Salute Network project, a 
large prospective registry of treated hypertensive women and men of similar age in 
the Italian region of Campania.46 In that study, carotid plaques were more than twice 
as common as in the FATCOR study, with a prevalence of 45% and 48% in 
overweight and obese patients, respectively.46 Prevalent obesity was associated with 
17% higher prevalence of carotid plaque after adjustment for confounders like BP, 
age and sex, but the association of obesity with carotid plaques was offset after 
further adjustment for serum triglycerides and presence of diabetes .46 Additionally, 
they found that women had a 40% lower prevalence of carotid plaques than men.46 
This sex-difference has previously been documented,109 and is also present in the 
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FATCOR cohort. Compared to the FATCOR study, which included 60% 
women, a lower prevalence of women was included in the study by Mancusi et al., in 
which 36% of the overweight patients and 44% of the obese patients were women.46 
Considering the aforementioned sex-difference in prevalence of carotid plaque, it is 
likely that our higher prevalence of women could have contributed to the lower 
observed prevalence of carotid plaque.   
The average pulse wave velocity in the FATCOR population was within 
normal range and did not differ by fitness. Studies on pulse wave velocity in relation 
to fitness in adults with increased BMI are scarce, but a study of 166 sedentary, 
middle-aged, obese subjects indicated that higher fitness, quantified by maximal 
exercise testing, was associated with lower pulse wave velocity.110 Generalization of 
those results to our population is complicated by the fact that brachial-ankle pulse 
wave velocity was used in that study, which is not in line with current guideline 
recommendations on how to assess arterial stiffness.82 Furthermore, their study 
population included a high prevalence of diabetes, which may have influenced their 
results, and also reduce the generalizability of the results.110 Thus, further studies are 
needed to ascertain the impact of fitness on pulse wave velocity in obesity.  
10.2.2 Left atrial dilatation 
The total prevalence of LA dilatation was 67%, and it was the most common type of 
subclinical cardiac disease in the FATCOR population. That LA dilatation was 
present in the majority in our overweight and obese cohort may partly be explained 
by the LA’s vulnerability to increased pressure- and volume overload,111 as is the 
case in subjects with increased BMI.41 The independent association between 
increasing BMI and prevalent LA dilatation has previously been established in 
hypertensive patients with electrocardiographic signs of LV hypertrophy53, 112 and in 
the general population.43 For example, in a population-based cohort from Germany, 
results from 10 years of follow-up showed that, apart from aging, obesity was the 
most powerful predictor of incident LA dilatation in women and men.43 Additionally, 
both hypertension and obesity were identified as independent predictors of incident 
LA dilatation, and interestingly, the joint effects on these differed by sex.43 
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Normotensive, obese women and men had similar prevalences of LA 
dilatation, but in co-presence of hypertension, the prevalence of LA dilatation was 2-
fold in women compared to men.43 Similarly, women had a higher prevalence of LA 
dilatation than men in an elderly population with LV hypertrophy and 
hypertension.113 The present results add to current knowledge by showing that LA 
dilatation is highly prevalent in middle-aged overweight and obese subject without 
known CV disease. Further, our results demonstrated that although the prevalence of 
obesity did not differ by sex, and despite that hypertension was more common in 
men, overweight and obese women had a more than 2-fold risk of prevalent LA 
dilatation compared to men. The presence of LA dilatation is clinically important as it 
is a predictor of CV morbidities such as atrial fibrillation and stroke.53-55 In addition, 
the risk of CV mortality is particularly high if LA dilatation is present in elderly 
women with atrial fibrillation.55 Studies have also shown that prevalent LA dilatation 
is more common in elderly women with LV hypertrophy and in obese, hypertensive 
women compared to their male counterparts.43, 113 
10.2.3  Abnormal left ventricular geometry 
In the FATCOR project, abnormal LV geometry was present in 25% of the 
participants. Obesity is known to cause LV remodeling in both women and men,114 
and the risk is demonstrated to be higher in obese women,21 especially if hypertension 
is co-present.50 In a cohort of adult Americans, the prevalence of LV hypertrophy in 
hypertensive subjects was tripled in obese women compared to lean women, while 
the prevalence was doubled in obese men compared to lean men.50 The Strong Heart 
Study, a population based study in free-living North American Indians, also 
demonstrated that women were at particular risk of obesity-associated LV 
remodeling, and that this persisted after adjustment of known CV risk factors like 
history of hypertension, actual systolic BP and age.21 In the Strong Heart Study they 
also found that high LV mass in women was particularly associated with other 
indicators of obesity, such as body fat mass and waist-to-hip ratio.21 In contrast, in the 
FATCOR cohort, we found that men had a higher prevalence of abnormal geometry, 
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and also higher prevalences of LV hypertrophy and concentric LV geometry. 
Furthermore, the presence of abnormal LV geometry was not associated with  
any other indicators of obesity in the FATCOR cohort, neither among women nor 
among men. Compared to the current study, in which obesity did not differ by sex 
and the co-presence of obesity and hypertension was more common in men, the 
Strong Heart Study had a much higher prevalence of obese, hypertensive women.21 It 
is possible that these differences in population characteristics can contribute to 
explaining the diverging results. The powerful impact of co-presence of hypertension 
and obesity on LV geometry has previously been demonstrated in the prospective 
Campania Salute Network registry, which found that obese, hypertensive subjects had 
a 7-fold higher prevalence of LV hypertrophy compared to normal-weight, 
hypertensive subjects.46 
Although the mechanisms are unclear, current knowledge suggests that obesity 
is associated with a higher prevalence of concentric LV geometry.41 In the current 
study we could not find that prevalent concentric LV geometry was associated with 
any measures of body composition or BP, but rather that the only factor retaining 
significance in multivariable analysis in the total study population was higher age. 
This is in contrast to the Multi-Ethnic Study of Atherosclerosis, which in more than 
5,000 adults found that obesity was associated with prevalent concentric LV 
geometry.115 The much larger and older sample in that study, combined with the use 
of cardiac magnetic resonance imaging, may help explain the differing results.        
10.2.4  Left ventricular systolic function 
In hypertension, overweight and obesity have been associated with reduced LV 
systolic function measured by LV ejection fraction and stress-corrected midwall 
shortening.42 In a healthy population-based cohort, every 5 unit increase in BMI was 
associated with 5% reduction of GLS.75 In the FATCOR population, LV systolic 
function evaluated by LV ejection fraction and GLS was on average normal. 
However, when analyzing the prevalences of abnormal LV systolic function after 
applying sex-specific cut-offs,40, 87 we found that the prevalences of abnormal GLS 
were much higher than the prevalences of abnormal LV ejection fraction. This is in 
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accordance with previous studies that have demonstrated that GLS is a more 
sensitive method to detect reduction in LV systolic function than LV ejection 
fraction.72, 73 For example, the prevalence of abnormal GLS was 4 times as high as 
the prevalence of abnormal LV ejection fraction in an American population-based 
study of 708 middle-aged and elderly subjects without known coronary heart 
disease.72 These findings were expanded in another publication from the same cohort, 
in which they explored the impact of general obesity, assessed by BMI, and of 
abdominal adiposity, assessed by waist-hip ratio and waist circumference, on LV 
systolic function.116 In that study they found that increased waist-hip ratio and waist 
circumference were independently associated with reduced GLS but not with reduced 
LV ejection fraction in both non-obese and obese subjects.116 Furthermore, they 
found no association between BMI and GLS, but that increasing BMI was associated 
with higher LV ejection fraction.116 In line with this, we found the lowest average 
GLS and the highest prevalence of abnormal GLS in the unfit obese group, which 
was the group with highest waist circumference. The obese subjects had higher LV 
ejection fraction than overweight subjects.  
 In the FATCOR cohort, fitness was independently associated with higher GLS 
in obese subjects, but not in overweight subjects. Previously, an univariable 
association between fitness and lower GLS was reported in a small cross-sectional 
study of 9 obese adolescents.79 Unfortunately this association could not be examined 
in multivariable analyses in their study due to too few observations.79 In contrast, in a 
cross-sectional study by Share et al. that included 39 obese young females and 33 
controls without obesity, no significant association of physical activity with GLS was 
found.78 Also, LV myocardial function, assessed by tissue Doppler strain, was 
negatively associated with BMI in a population of 142 participants with increased 
BMI without known diabetes or hypertension.117 In that population there was no 
association between LV myocardial function and peak oxygen uptake obtained by 
exercise testing.117 The present project adds to current knowledge by showing that the 
negative impact of increased BMI on LV systolic function can be demonstrated in 
obesity, but not in overweight subjects, and although fitness did not impact prevalent 
abnormal LV geometry, a positive association between being fit and a more negative 
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GLS was identified. Our findings suggest that a reduction in body fat mass 
percentage through physical activity resulting in higher fitness may result in 
improved LV systolic function in obesity. However, this remains to be tested  
in a prospective study with repeated measures of exercise capacity, LV systolic 
function and body composition. 
10.3 Limitations 
The present project has some important limitations. The FATCOR study was 
cross-sectional in design, thus cause-effect relationships could not be documented. 
The FATCOR cohort was characterized by middle-age, obesity and absence of 
known clinical CV disease. Extrapolation of results from this cohort to other 
populations must therefore be done with caution. Also, we did not have information 
about duration of obesity or current fitness level, and it is possible that this 
information would have added to our results. 
Another limitation is that some data was missing in all studies. This was 
caused by participants not showing for ergospirometry testing despite repeated 
invitations or due to poor echocardiographic imaging quality. Furthermore, we 
decided to analyze GLS using speckle tracking echocardiography and the EchoPac 
algorithm, which limited the study population in the 3rd study to those that had 
echocardiography performed by a GE machine. Potentially, these factors may have 
introduced selection biases to the substudies. However, the excluded participants did 
not differ significantly by age or BMI to the included participants. Obesity is often 
associated with reduced echocardiographic image quality. However, only 6.7% of 
patients had image quality too low for quantification of LV geometry, and another 
10.5% had image quality too low for speckle tracking echocardiographic analysis of 
GLS. The use of a high-quality core laboratory for all echocardiographic analyses 
contributed to reproducible and high quality image analyses, and follows 
recommendations for echocardiography in clinical studies, strengthening the study 
design. 
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Finally, the bioelectrical impedance analysis was performed by a 
tetrapolar device with a foot-foot system. Compared with a hand-foot system, this 
method can somewhat underestimate lean body mass, as well as overestimate fat 
mass in women and underestimate fat mass in men. Another potential limitation is 
that we did not scale peak oxygen uptake for body composition. Optimally we should 
have provided both scaled and unscaled results, as both methods are associated with 
their own sets of misclassifications.118 However, this recently published information 
was not available to us when the FATCOR project started in 2009. 
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11. Future perspectives 
The present project demonstrated that CV risk factors were highly prevalent in the 
FATCOR cohort, and that these were often unknown both to the patient and to the 
attending general practitioner. This observation suggests that subjects with increased 
BMI should be recommended thorough evaluation of CV risk organized by the 
primary health care physician, and that general practitioners should be reminded that 
targeted more in-depth CV risk assessment, like 24-h BP monitoring and oral glucose 
tolerance testing, may be necessary even in apparently healthy, middle-aged obese 
subjects without obvious CV disease. The present results also demonstrated that 
subclinical cardiac disease was highly prevalent in middle-aged subjects with 
increased BMI. Considering the prognostic implications of prevalent subclinical 
cardiac disease, our results point to the benefit of integration of echocardiography in 
CV risk assessment in subjects with increased BMI.  
 Prospective studies including frequent and repeated measures of exercise 
capacity, body composition and CV imaging should be conducted to further explore 
the impact of duration of fitness and fatness on CV health. Knowledge from 
randomized-controlled exercise and weight loss intervention studies with CV imaging 
could provide information on how to best prevent and treat subclinical CV disease in 
overweight and obese women and men. 
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12. Conclusions 
We hypothesized that fitness was associated with lower prevalences of CV risk 
factors and subclinical CV disease in overweight and obese women and men without 
known clinical CV disease. As demonstrated in this thesis, fitness was not associated 
with lower prevalences of CV risk factors and subclinical disease, but fitness was, 
associated with better LV systolic myocardial function in obese subjects.  
 
Study 1 
The purpose of study 1 was to assess the association of fitness with prevalence of 
CV risk factors and subclinical arterial disease in overweight and obese women 
and men without known clinical CV disease. 
Conclusion: Fitness status did not impact the prevalence of major CV risk factors 
like hypertension, metabolic syndrome and diabetes, or subclinical arterial disease. 
Prevalent carotid plaque was more common in men than in women.  
 
Study 2 
The purpose of study 2 was to assess the association of fitness with subclinical 
cardiac disease in overweight and obese women and men without known clinical 
CV disease. 
Conclusion: Fitness was not associated with lower prevalence of subclinical cardiac 
disease. The majority of the participants in the FATCOR study had subclinical 
cardiac disease. LA dilatation was the most common type of subclinical cardiac 
disease. Women had a 2-fold higher risk of subclinical cardiac disease, in particular 
LA dilatation, while men had a 2-fold higher risk of abnormal LV geometry. 
 
Study 3 
The purpose of study 3 was to assess the effect of fitness on LV myocardial 
function in overweight and obese women and men without known clinical CV 
disease. 
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Conclusion: In obese subjects, fitness was associated with better LV systolic 
myocardial function assessed by GLS. Fitness did not impact LV systolic myocardial 
function in overweight subjects. By adding GLS to evaluation of LV systolic 
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Abstract Background and aims: Good cardiorespiratory fitness has been suggested to reduce the
risk of cardiovascular disease in obesity. We explored the association of fitness with the preva-
lences of major cardiovascular risk factor like hypertension (HT), diabetes and metabolic syn-
drome (MetS) in overweight and obese subjects.
Methods and results: Clinical data from 491 participants in the FAT associated CardiOvasculaR
dysfunction (FATCOR) study were analyzed. Physical fitness was assessed by ergospirometry,
and subjects with at least good level of performance for age and sex were classified as fit. HT sub-
types were identified from clinic and 24-h ambulatory blood pressure in combination. Diabetes
was diagnosed by oral glucose tolerance test. MetS was defined by the American Heart Associa-
tion and National Heart, Lung and Blood Institute criteria. The participants were on average 48
years old (60% women), and mean body mass index (BMI) was 32 kg/m2. 28% of study partici-
pants were classified as fit. Fitness was not associated with lower prevalences of HT or HT sub-
types, diabetes, MetS or individual MetS components (all p > 0.05). In multivariable regression
analysis, being fit was characterized by lower waist circumference, BMI < 30 kg/m2, non-
smoking and a higher muscle mass (all p < 0.05).
Conclusion: In the FATCOR population, fitness was not associated with a lower prevalence of ma-
jor cardiovascular risk factors like HT, diabetes or MetS. Given the strong association of cardio-
vascular risk factor burden with risk of clinical cardiovascular disease, these findings challenge
the notion that fitness alone is associated with lower risk of cardiovascular disease in obesity.
ª 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.
Introduction
Physical inactivity and poor cardiorespiratory fitness are
considered independent risk factors for cardiovascular
(CV) disease [1]. Cross-sectional data from the FINRISK
study indicate that fitness is associated with a healthier CV
risk profile independent of the level of abdominal
adiposity [2]. The Nurses’ Health Study and the Aerobics
Center Longitudinal Study comparing CV outcomes be-
tween fit obese subjects and unfit obese subjects, found
lower CV morbidity and mortality in the fit group [3e6].
From this it may be suggested that the increased CV risk
posed by obesity may be reduced by improving cardiore-
spiratory fitness [1].
* Clinical trial registration: URL: http://www.clinicaltrials.gov
NCT02805478.
* Corresponding author. Department of Clinical Science, University of
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Despite the large amount of evidence from population-
based studies supporting the importance of maintaining
fitness for CV health, few clinical studies in obese subjects
have tested the relationship between cardiopulmonary
fitness measured by maximal oxygen uptake and CV risk
factors, and inconsistent results have been reported [7,8].
In the present study, we tested the hypothesis that good
cardiorespiratory fitness is associated with an improved
CV risk factor profile in an overweight and obese cohort. In
particular, the influence of cardiorespiratory fitness on the
prevalence of major CV risk factors like hypertension (HT),
diabetes and metabolic syndrome (MetS) was targeted.
Methods
Study population
Clinical data were collected from the ongoing FAT associ-
ated CardiOvasculaR dysfunction (FATCOR) study at Hau-
keland University Hospital in Bergen, Norway. The study
included women and men aged 30e65 years old with a
body mass index (BMI) > 27 kg/m2. Exclusion criteria were
previous myocardial infarction, gastrointestinal disorder,
severe psychiatric illness or the inability to understand
Norwegian language. Inclusion into the study was per-
formed at a collaborating general practice center special-
izing in management of obesity. A total of 510 participants
were recruited from October 2009 to November 2015. Of
these, 491 participants had completed ergospirometry and
were included in the present analysis. The FATCOR study
was conducted in accordance with the Declaration of
Helsinki from 1983 and with approval from the Regional
Ethics Committee. Written informed consent was signed
by all participants.
Cardiovascular risk assessment
Following inclusion, all participants underwent a clinical
examination at the general practitioner center. Clinic blood
pressure (BP) was measured using appropriate cuff-size
(Omron M4 sphygmomanometer, Omron Healthcare Co.
Ltd., Hoofddorp, Netherlands) in accordance with current
guidelines [9]. Bioelectrical impedance analysis (Tanita-TBF-
300A, Tanita Corporation of America, Arlington Heights,
USA)was used for body composition analysis. Blood glucose
and lipid profile were measured in fasting, venous blood
samples [10]. An oral glucose tolerance test was performed
in all participantswithout knowndiabetes and fasting blood
glucose < 7.0 mmol/L. The participants’ self-reported gen-
eral health was recorded using a standardized question-
naire, which also included declaration of hours of physical
activity per week and use of any medication.
The World Health Organization definition was used for
identification of overweight and obesity [11]. The Amer-
ican Heart Association/National Heart, Lung and Blood
Institute criteria were used to identify MetS [12]. MetS was
diagnosed if at least three of the following five criteria
were present in the individual participant: 1) waist
circumference 88 cm (women) and 102 cm (men),
2) triglycerides  1.7 mmol/L, 3) high-density lipoprotein
(HDL) cholesterol <1.3 mmol/L (women) and <1.03 mmol/
L (men), 4) systolic BP  130 mmHg and/or diastolic
BP  85 mmHg and/or antihypertensive treatment or 5)
fasting blood glucose  5.6 mmol/L and/or drug treatment
for elevated blood glucose. Diabetes was considered pre-
sent if history of diabetes, fasting blood glucose  7 mmol/
L, glycated hemoglobin A1c (HbA1c)  6.5% or 2-h blood
glucose  11.1 mmol/L after oral glucose tolerance testing
was found [13]. A fasting blood glucose between 5.6 and
6.9 mmol/L was recognized as impaired fasting blood
glucose (IFG) and a 2-h blood glucose 7.8e11.0 mmol/L was
recognized as impaired glucose tolerance (IGT) [13].
24-h ambulatory BP recording
The participants underwent a 24-h ambulatory BP (24-h
BP) recording (Diasys Integra II, Novacor, Cedex, France) as
previously described [14]. An appropriately sized cuff was
placed on the non-dominant arm. The equipment was set
to perform BP measurement every 20 min during day-time
and every 30 min during night-time. The participants were
instructed to adhere to their daily routines, apart from
abstaining from strenuous exercise, and to relax their arm
during measurements. If <70% of the measurements were
valid, the 24-h BP recording was repeated. In accordance
with the current guidelines for management of arterial HT
[9], the results from measurement of clinic BP and 24-h BP
recording were used for identifying normotension (NT),
white-coat hypertension (WCHT), masked hypertension
(MHT) and sustained hypertension (SHT). NT was defined
as clinic BP < 140/90 mmHg and 24-h BP < 130/80 mmHg.
WCHT was considered present if elevated clinic, but
normal 24-h BP was found, and MHT if normal clinic, but
elevated 24-h BP was found. SHT was considered present if
both clinic and 24-BP was elevated. Patients treated with
antihypertensive drugs were classified as SHT irrespective
of actual BP measurements.
Subclinical arterial disease
Aortic stiffness was measured with applanation tonometry
(SphygmoCor, AtCor Medical, Sydney, West Ryde,
Australia), derived from carotid-femoral pulse wave ve-
locity (PWV), as previously described [15]. In accordance
with current guidelines [9], PWV > 10 m/s was taken as
increased aortic stiffness. Carotid intima-media thickness
(cIMT) was measured by ultrasound (Phillips iE33, Phillips
Healthcare, Best, Netherlands) and considered increased if
mean cIMT > 0.9 mm. Carotid plaque was considered
present if focal cIMT  1.5 mm [9].
Exercise capacity and fitness
Peak oxygen uptake (VO2max) was measured by ergo-
spirometry using a treadmill (Schiller CS-200, Schiller AG,
Baar, Switzerland) and a standardized protocol (Chrono-
tropic Assessment Exercise Protocol) in all participants [16].
The respiratory exchange ratio was measured by breath-to-
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breath technique. The participants were encouraged to
continue the test until volitional exertion. The classification
by Shvartz and Reibold for sex- and age specific identifica-
tion of cardiorespiratory fitness based upon peak VO2max
was used to identify fit and unfit participants [17]. Based
upon peak VO2max cardiopulmonary fitness was rated as
very poor, poor, fair, average, good, and very good to
excellent. We classified the participants as fit if they ach-
ieved at least good peak VO2max for sex and age (Table 1).
Statistics
Data management and statistical analyses were performed
using the IBM SPSS Statistics software version 22 (IBM,
Armonk, New York, USA). The study population was
grouped into fit and unfit groups. Data are presented as
mean  standard deviation (SD) for the continuous vari-
ables and as percentages for categorical variables. Groups
were compared with Chi-square test for categorical vari-
ables and with unpaired Student’s t-test for continuous
variables. A general linear model with Scheffe’s post-hoc
test was used for comparison between BP categories.
Uni- and multivariable logistic regression analyses were
used to identify covariables of being fit in the study pop-
ulation. Important covariables from univariable analyses
were selected for the multivariable model. The results are
presented as odds ratio (OR) with 95% confidence intervals




The 491 FATCOR participants were on average 48  9 years
old, 60% were women and the average BMI was 32  4 kg/
m2 (Table 1). Of these, 28% of the participants were clas-
sified as fit.
Comparison of fit and unfit subjects
The fit and unfit groups had comparable prevalence of HT
(p > 0.05). Use of antihypertensive treatment was com-
parable between fit and unfit groups (Table 2), and the
prevalences of different HT subtypes did not differ (both
p > 0.05) (Fig. 1). The prevalence of newly diagnosed HT in
the study was high (30% in unfit vs. 33% in fit groups
(pZ 0.57)). Both 24-h systolic and mean BP were higher in
the unfit group (p < 0.05), while clinic BP did not differ
(Table 3).
The unfit group had a higher prevalence of obesity and
higher fat mass and waist circumference compared to the
fit group (all p < 0.001), while the prevalence of MetS did
not differ between the groups (pZ 0.12) (Table 2). Also the
prevalences of individual components of MetS were
similar (all p > 0.05) (Fig. 2). Newly diagnosed diabetes in
the study was found in 5% of unfit and 7% of fit subjects
(p Z 0.50) (Table 2). Glucose control, evaluated by HbA1c,
did not differ between fit and unfit diabetic subjects
(6.1  1.0 vs. 6.1  0.8, p Z 0.097).
Table 1 Identification of fit subjects based upon sex and age specific threshold values for at least good peak O2 uptake during maximal treadmill
testing.
Age groups (years) 30e34 35e39 40e44 45e49 50e54 55e59 60e65
Threshold for fitness
in women (ml/kg/min)
>38.2 >37.2 >34.2 >33.8 >30.8 >27.8
Threshold for fitness
in men (ml/kg/min)
>49.6 >51.4 >46.7 >43.3 >40.2 >39.0 >38.6









Women, % 60 59 60 0.92
Age, years 48  9 47  9 51  9 <0.001
VO2max, ml/kg/min 31  7 29  6 37  8
Body weight, kg 96  16 99  17 86  11 <0.001




108  11 110  11 102  9 <0.001
Hip circumference,
cm
116  12 117  12 111  10 <0.001
Fat mass, kg 36  11 38  11 30  7 <0.001
Obesity, % 63 73 38 <0.001
Physical activity,
h/wk
3.9  2.7 3.6  2.6 4.6  2.8 <0.001
Current smoking, % 14 15 9 0.07
Self-reported
diabetes, %
7 7 5 0.54
In-study diagnosed
diabetes, %
5 5 7 0.50
Total diabetes, % 12 12 12 1.00
In-study diagnosed
HT, %
28 27 31 0.57
Total HT, % 61 63 58 0.35
Antihypertensive
treatment, %
57 59 51 0.45
MetS, % 45 47 39 0.12
Triglycerides,
mmol/L
1.5  0.8 1.5  0.9 1.4  0.7 0.07
HDL-cholesterol,
mmol/L
1.3  0.3 1.3  0.3 1.3  0.3 0.97
Fasting blood
glucose, mmol/L
5.4  1 5.4  1 5.3  1 0.07
Impaired fasting
glucose, %
20 21 18 0.61
Impaired glucose
tolerance, %
7 7 8 1.00
VO2max, peak oxygen uptake; BMI, body mass index; DM, diabetes
mellitus; HT, hypertension; MetS, metabolic syndrome; HDL, high-
density lipoprotein.
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Subclinical arterial disease was rare in the population,
and did not differ between fit and unfit groups (Table 3).
Covariates of fitness in uni- and multivariable analyses
In univariable logistic regression higher age, body mass
index (BMI) < 30 kg/m2, lower waist and hip circumfer-
ences, lower fat mass, lower 24-h mean BP, higher self-
reported physical activity and a higher muscle mass as
percentage of body weight were all associated with being
fit (all p < 0.001) (Table 4). In multivariable regression
analysis, lower waist circumference, BMI < 30 kg/m2,
being a non-smoker and having a higher muscle mass as
percentage of body weight were all identified as inde-
pendent covariables of being fit (all p < 0.05) (Table 4).
Discussion
The current study explored if fitness was associated with a
more favorable CV risk profile in overweight and obese
subjects without known CV disease participating in the
FATCOR study. As demonstrated, prevalences of major CV
risk factors like HT, MetS and diabetes did not differ be-








Normotension White-coat hypertension Masked hypertension Sustained hypertension
All p>0.05
Unfit Fit
Figure 1 Prevalences of blood pressure categories in fit and unfit groups.









Systolic BP, mmHg 130  16 130  16 132  17 0.28
Diastolic BP, mmHg 83  10 83  10 83  9 0.89
Pulse, beats/min 68  10 68  10 66  10 <0.05
24-h BP
24-h systolic BP, mmHg 122  12 122  13 120  11 <0.05
24-h diastolic BP, mmHg 79  8 80  8 78  7 0.13
24-h mean BP, mmHg 94  8 94  9 92  8 <0.05
Elevated 24-h BP, % 68 70 62 0.14
Day-time systolic BP, mmHg 125  13 126  13 123  12 0.06
Day-time diastolic BP, mmHg 81  8 82  8 81  7 0.13
Day-time mean BP, mmHg 96  9 97  9 95  8 <0.05
Night-time systolic BP, mmHg 109  19 109  13 108  29 0.65
Night-time diastolic BP, mmHg 70  9 71  9 70  8 0.25
Night-time mean BP, mmHg 83  9 84  10 82  8 <0.05
Subclinical arterial disease
PWV, m/s 7.5  1.7 7.6  1.6 7.4  1.8 0.39
PWV > 10 m/s, % 7 7 7 1.00
Mean cIMT, mm 0.77  0.21 0.78  0.22 0.76  0.17 0.30
Increased cIMT, % 19 20 15 0.23
Carotid plaque, % 21 23 19 0.40
BP, blood pressure; PWV, pulse wave velocity; cIMT, carotid intima-media thickness.
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HT subtypes or individual components of MetS was found
between the fit and unfit groups, and subclinical arterial
disease like increased arterial stiffness or carotid athero-
sclerosis was uncommon in both groups, despite the high
CV risk factor burden.
Our results clearly demonstrate the benefit from thor-
ough and comprehensive CV risk assessment in subjects
with increased BMI. A total of 46% of HT and 42% of dia-
betes cases were diagnosed as a result of the FATCOR study
program, pointing to the benefit of systematic use of 24-h
BP and oral glucose tolerance test for optimization of CV
risk factor identification in overweight and obese subjects.
Overall, HT was found in 61% in the current FATCOR pop-
ulation, reflecting the known association between obesity
and HT [18]. In comparison, HT was found in 30% of
women and in 50% of men of similar age range in a
representative subset of general Norwegian population
[19]. The higher prevalence of HT in our FATCOR popula-
tion may be attributed to obesity, but we also used 24-h BP
to optimize the detection of HT [20]. However, the prev-
alences of white-coat and masked hypertension were low
in our study population [14,21]. Of note, the fit group had
significantly lower 24-h mean BP, despite comparable
prevalence of HT and use of antihypertensive drug
treatment. The lack of influence of higher cardiorespira-
tory fitness on prevalent hypertension was also previously
reported from the National Health and Nutrition Survey
(NHANES) [7].
The total prevalence of MetS was 45% in the current
study population. In comparison, MetS has been reported
in 28% of women and 22% of men of similar age in general
Norwegian population [22]. A cross-sectional study of
healthy police employees in the Netherlands found
cardiorespiratory fitness to be associated with less clus-
tering of risk factors [23]. Furthermore, Kouki et al. found
that cardiorespiratory fitness was more closely associated
with prevalent MetS than diet [8]. However, in the present
study, the prevalence of MetS did not differ between fit
and unfit groups, despite both BMI and fat mass being
significantly lower in the fit group and the independent
association of fitness with lower waist circumference in
multivariate analysis. In the FINRISK study [2], an associ-
ation of fitness with lower BP and serum lipid levels was
particularly observed in men with the highest waistehip
ratio. However, that study used estimated and not
measured cardiorespiratory fitness.
The total prevalence of diabetes in the FATCOR popu-
lation was 12%, 3-fold higher than in general Norwegian




Low high-density lipoprotein 
cholesterol
Impaired glucose tolerance All p>0.05
Fit Unfit
Figure 2 Prevalences of individual components of metabolic syndrome in fit and unfit groups.
Table 4 Covariables of being fit in the total study population.
Variables Univariable analysis Multivariable analysis
OR 95% CI p OR 95% CI p
Non-obesity 4.43 2.92e6.74 <0.001 2.00 1.17e3.41 0.011
Waist circumference, cm 0.93 0.90e0.95 <0.001 0.94 0.92e0.97 <0.001
Hip circumference, cm 0.93 0.90e0.95 <0.001
Fat mass, kg 0.91 0.88e0.93 <0.001
BMI, kg/m2 0.72 0.66e0.79 <0.001
Muscle mass, % 1.06 1.03e1.09 <0.001 1.05 1.01e1.08 0.004
Non-smoking 1.91 0.96e3.80 0.06 2.64 1.19e5.86 0.017
Physical activity, h/wk 1.15 1.06e1.24 <0.001
Day-time mean BP, mmHg 0.97 0.95e1.00 0.04
Day-time HR, beats/min 0.96 0.93e0.98 <0.001
Night-time mean BP, mmHg 0.97 0.95e1.00 0.04
OR, odds ratio; CI, confidence interval; BMI, body mass index; BP, blood pressure; HR, heart rate.
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population, and did not differ between fit and unfit groups
[24]. A clinical study of obese subjects with type 2
diabetes found that a low level of cardiorespiratory fitness
was associated with a higher risk of all-cause mortality,
stroke and myocardial infarction independent of abdom-
inal obesity [25]. Prospective studies in both women and
men have found that fitness reduced, but did not fully
compensate for the increased risk of diabetes in obesity
[26,27]. However, in the Strong Heart Family Study, Fretts
et al. found that even a moderate physical activity
measured by a pedometer was associated with a 25%
reduced risk for incident diabetes in obese subjects [28].
Study limitations
Given the cross-sectional design of our study, causeeeffect
relations could not be explored. The majority of the par-
ticipants were recruited at a general practitioner center
that also offered organized weight reduction programs.
Since most patients were included without delay, it is
possible that the positive effects on CV risk factors exerted
by fitness had not yet become evident. The fact that mean
24-h BP was lower in the fit group despite similar preva-
lences of HT and HT subtypes illustrates this possibility.
Unfortunately the duration of the reported level of phys-
ical activity was not captured by the questionnaire applied
in the FATCOR study. A small study in older obese subjects
demonstrated that insulin sensitivity measured by the
euglycemic hyperinsulinemic clamp improved by 21% after
16 weeks of moderate exercise training [29]. Since preva-
lent hypertension increases with age, the age difference
between the groups may have contributed to the lack of
difference in prevalent hypertension between the groups.
The influence of obesity and MetS on cardiac structure
and function is well known, and presence of diastolic
dysfunction as well as left ventricular hypertrophy could
have influenced VO2max [30]. However, these factors were
not assessed in the present study.
Conclusions
Cardiorespiratory fitness was not associated with a lower
burden of major CV risk factors like HT, MetS and diabetes
in the overweight and obese FATCOR population. Given the
known association of CV risk factor burden with risk for
clinical CV disease, these findings challenge the notion that
cardiorespiratory fitness alone reduces risk for CV disease
in obesity. The benefits from including 24-h ambulatory BP
recording and oral glucose tolerance test in a thorough and
comprehensive CV risk assessment in subjects with
increased BMI were clearly demonstrated.
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Abstract Background and aims: Subclinical cardiac disease, like abnormal left ventricular (LV)
geometry or left atrial (LA) dilatation, is common in obesity. Less is known about sex differences
in the prevalence and type of subclinical cardiac disease in obesity.
Methods and results: Clinical and echocardiographic data from 581 women and men without es-
tablished cardiovascular disease and body mass index (BMI) > 27.0 kg/m2 participating in the
FAT associated CardiOvasculaR dysfunction (FATCOR) study was analyzed. LA dilatation was
recognized as LA volume indexed for height2 16.5 ml/m2 in women and 18.5 ml/m2 in
men, and abnormal LV geometry as LV hypertrophy and/or increased relative wall thickness.
On average, the participants were 48 years old, 60% women and mean BMI was 32.1 kg/m2. Over-
all, the prevalence of subclinical cardiac disease was higher in women than men (77% vs. 62%,
p < 0.001). Women had a higher prevalence of LA dilatation than men (74% vs. 56%,
p < 0.001), while men had a higher prevalence of abnormal LV geometry (30% vs. 21%,
p Z 0.011). After adjusting for confounders in multivariable logistic regression analysis, female
sex was associated with a 2-fold higher risk of subclinical cardiac disease, in particular LA dila-
tation (confidence interval [CI] 1.67e3.49, p < 0.001), while male sex was associated with a 2-
fold higher risk of abnormal LV geometry (CI 1.30e3.01, p Z 0.001).
Conclusion: The majority of overweight and obese participants in the FATCOR study had subclin-
ical cardiac disease, which may contribute to the impaired prognosis observed in obesity.
Women had a higher prevalence of subclinical cardiac disease than men.
Clinical trial registration: URL: http://www.clinicaltrials.gov NCT02805478.
ª 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery,
Federico II University. Published by Elsevier B.V. All rights reserved.
Introduction
Presence of subclinical cardiac disease like left atrial (LA)
dilatation, left ventricular hypertrophy (LVH) and
abnormal left ventricular (LV) geometry, is associated with
increased cardiovascular morbidity and mortality in hy-
pertension as well as in the general population [1e3].
Previous publications in hypertension have found sub-
clinical cardiac disease to be more prevalent among
women than men, in particular LVH and LA dilatation
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E-mail address: hilde.halland@uib.no (H. Halland).
https://doi.org/10.1016/j.numecd.2018.06.014
0939-4753/ª 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Nutrition, Metabolism & Cardiovascular Diseases (2018) 28, 1054e1060
Available online at www.sciencedirect.com
Nutrition, Metabolism & Cardiovascular Diseases
j ourna l homepage: www.e lsev ier .com/ locate /nmcd
[1,4,5]. Results from the Campania Salute Network registry
demonstrated that in treated hypertensive patients, female
sex and obesity was particularly associated with lack of
LVH regression independent of blood pressure control [6].
It is well demonstrated that also obesity is associated
with increased risk for subclinical cardiac disease [7e10].
In the Strong Heart Study, LVH was particularly prevalent
in obese women with low fat-free mass [9]. In a German
cohort, Stritzke et al. identified obesity as the main factor
associated with age-associated LA dilatation [10], espe-
cially in obese women with concomitant hypertension
[10]. Furthermore, in older patients with hypertension and
LVH, the association of higher pulse pressure, a crude
measure of arterial stiffness, with LA dilatation was
pointed out [5].
The current study aimed to further explore sex differ-
ences in the prevalence and type of subclinical cardiac




The present study is based on the FAT associated CardiO-
vascular dysfunction (FATCOR) study, which was per-
formed at Haukeland University Hospital, Bergen, Norway,
2009e2017. The study inclusion and exclusion criteria
have previously been described [11,12]. In short, the par-
ticipants were 30e65 years old and had a body mass index
(BMI) > 27.0 kg/m2. Exclusion criteria were previous
myocardial infarction, gastrointestinal disorder, severe
psychiatric illness or inability to understand Norwegian
language. A collaborating general practice center, with a
particular interest in the management of obesity, recruited
the participants. In total 620 participants were recruited.
Readable echocardiograms were obtained in 581 (94%) of
the participants, and these were included in the present
analysis. The FATCOR study was approved by the Regional
Ethics Committee and adhered to the Declaration of Hel-
sinki. All participants signed written informed consent
forms.
Cardiovascular risk assessment
A standardized questionnaire was used for self-reporting
of the participants’ general health, including use of any
medication. Clinic blood pressure was measured in
accordance with current guidelines using an Omron M4
sphygmomanometer (Omron Healthcare Co. Ltd., Hoof-
dorp, Netherlands) and a cuff of appropriate size for the
individual arm circumference [13]. Pulse pressure was
calculated from clinic blood pressure as the difference
between systolic and diastolic blood pressure. For the 24-
h ambulatory blood pressure recordings, a Diasys Integra
II apparatus (Novacor, Cedex, France) was used. Blood
pressure was recorded every 20 min during daytime and
every 30 min during nighttime, using a correctly sized
cuff on the non-dominant arm. The participants were
advised to avoid hard exercise and to relax their arm
during cuff inflation, but otherwise engage in normal
activities [13]. The 24-h blood pressure recording was
repeated if <70% of the measurements were valid. Hy-
pertension was considered present if participants used
any antihypertensive medication, or if 24-h ambulatory
blood pressure was elevated (average systolic 24-h blood
pressure 130 mmHg and/or average diastolic 24-h blood
pressure 80 mmHg) [11]. Dipping status was deter-
mined from the difference in mean systolic blood pres-
sure between day- and nighttime. Reverse dipping was
defined as an increase in mean systolic blood pressure
from day-to nighttime and non-dipping as a <10%
decrease in mean systolic blood pressure from day-to
nighttime.
A 2-h oral glucose tolerance test was performed in all
participants without known diabetes mellitus. Diabetes
mellitus was diagnosed if presence of history of diabetes
mellitus, or a positive 2-h oral glucose tolerance, elevated
fasting blood glucose or glycated hemoglobin A1c was
found, in accordance with the criteria from the American
Diabetes Association [14].
Body composition analysis was performed by tetrapolar
bioelectrical impedance analysis (Tanita-TBF-300A, Tanita
Corporation of America, Arlington Heights, USA). Obesity
and overweight in the participants was identified by
applying the World Health Organization criteria. Metabolic
syndrome was diagnosed by the American Heart Associa-
tion/National Heart, Lung and Blood Institute definition
[15]. The Chronic Kidney Disease Epidemiology Collabo-
ration equation was used for calculating estimated
glomerular filtration rate.
Echocardiography
Echocardiography was performed following a standard-
ized imaging protocol using a GE Vivid E9 scanner (GE
Vingmed Ultrasound, Horten, Norway). All images were
analyzed in the Echocardiography Core Laboratory at the
University of Bergen, Bergen, Norway on workstations
equipped with Image Arena software version 4.1 (TomTec
Imaging Systems GmbH, Unterschleissheim, Germany)
[16]. Images were first read by junior investigators, and
then all proofread by a single expert reader (EG), as rec-
ommended for clinical trials [17].
Quantitative echocardiography was performed in
accordance with the current guidelines [18]. LA dilatation
was defined as LA systolic volume indexed for height2
16.5 ml/m2 in women and 18.5 ml/m2 in men, reflect-
ing the upper 95th percentile of LA volume index in
healthy European populations [19]. LVH was considered
present if LV mass indexed for height2.7 exceeded the
prognostically validated cut-off values of >46.7 g/m2.7 in
women and >49.2 g/m2.7 in men [20]. Concentric LV ge-
ometry was considered present if relative wall thickness
0.43 [18]. LV geometry was defined from relative wall
thickness and LV mass index in combination [18].
Abnormal LV geometry was considered present if LVH and/
or concentric LV geometry was detected. Subclinical
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cardiac disease was defined as any presence of LA dilata-
tion and/or abnormal LV geometry.
Statistics
The IBM SPSS Statistics software version 23 (IBM,
Armonk, New York, USA) was used for data management
and statistical analysis. To explore sex-differences, data
are reported by sex. Data are presented as
mean  standard deviation for the continuous variables
and as percentages for categorical variables. Group com-
parison was performed with Student’s T-test for contin-
uous variables and Chi-square test for categorical
variables. Uni- and multivariable logistic regression ana-
lyses were used to identify the covariables of LA dilata-
tion, concentric LV geometry, abnormal LV geometry and
subclinical cardiac disease in the FATCOR population, and
reported as odds ratio (OR) with 95% confidence intervals
(CI). A p-value <0.05 was considered statistical signifi-
cance in all analyses.
Results
Clinical characteristics
Onaverage, the participantswere 48 9 years old, 60%were
womenand63%were obese (Table 1).Womenhadhigher fat
mass (p < 0.001) and higher BMI (p Z 0.013) than men
(Table 1). Men had higher average clinic and 24-h blood
pressure values (all p < 0.001), and a higher prevalence of
hypertension (p < 0.001). The prevalences of obesity, dia-
betes mellitus and metabolic syndrome were comparable
between women and men (all p > 0.20) (Table 1).
LA dilatation
LA dilatation was the most common type of subclinical
cardiac disease, overall present in 67% of the participants
(Table 2). Women had a higher prevalence of LA dilatation
than men (74% vs. 56%, p < 0.001) (Table 2). In women, LA
dilatation was particularly associated with higher pulse
pressure (OR 1.03 [95% CI 1.01e1.05], p Z 0.012), while no
significant associations with age, BMI, fat mass, systolic
blood pressure, waist circumference or serum triglycerides
were found (all p > 0.11). In men, LA dilatation was asso-
ciated with higher fat-free mass (OR 1.04 [95% CI
1.00e1.07], p Z 0.041) and lower serum triglycerides (OR
0.75 [95% CI 0.57e1.00], p Z 0.046), but no significant
association were found with age, BMI, fat mass, waist
circumference, systolic blood pressure or pulse pressure
(all p > 0.06). In univariable logistic regression analyses in
the total study population, presence of LA dilatation was
associated with female sex (OR 2.20 [95% CI 1.54e3,30],
p < 0.001), but not with higher pulse pressure, BMI or age,
and not with presence of diabetes mellitus or use of
antihypertensive treatment (all p > 0.11). In multivariable
Table 1 Clinical characteristics of overweight and obese women and men.
Variable All (n Z 581) Women (n Z 351) Men (n Z 230) p-value
Women (%) 60
Age (years) 48  9 48  9 47  9 0.398
Body weight (kg) 96  16 91  15 103  14 <0.001
Height (cm) 172  9 167  6 180  7 <0.001
Body mass index (kg/m2) 32.1  4.1 32.4  4.5 31.5  3.6 0.013
Waist circumference (cm) 108  11 106  12 110  10 <0.001
Hip circumference (cm) 116  111 118  12 112  9 <0.001
Fat mass (kg) 36  11 40  10 31  9 <0.001
Obesity (%) 63 64 62 0.517
Current smoking (%) 13 12 14 0.417
Diabetes mellitus (%) 9 11 7 0.199
Clinic SBP (mmHg) 130  16 127  17 134  14 <0.001
Clinic DBP (mmHg) 82  9 80  9 85  10 <0.001
Clinic pulse pressure (mmHg) 48  11 46  12 49  10 0.001
24-h SBP (mmHg) 121  12 119  12 124  11 <0.001
24-h DBP (mmHg) 79  8 78  8 82  7 <0.001
Hypertension (%) 60 53 72 <0.001
Treated hypertensive participants (%) 34 38 30 0.150
SBP daytime (mmHg) 126  13 123  13 129  12 <0.001
SBP nighttime (mmHg) 109  13 107  13 111  13 0.00
Non-dipping (%) 27 27 26 0.832
Reverse dipping (%) 2 3 2 0.866
Fasting blood glucose (mmol/L) 5.3  0.9 5.2  0.8 5.5  1.0 <0.001
HbA1c (%) 5.6  0.5 5.6  0.5 5.6  0.6 0.642
Total cholesterol (mmol/L) 5.4  1.1 5.5  1.1 5.3  1.1 0.052
HDL-cholesterol (mmol/L) 1.3  0.3 1.4  0.3 1.1  0.3 <0.001
Triglycerides (mmol/L) 1.5  1.1 1.4  1.1 1.7  1.0 0.004
Creatinine (mmol/l) 73  13 66  10 81  11 <0.001
eGFR (ml/min/1.73 m2) 96  13 95  14 97  12 0.105
Metabolic syndrome (%) 48 47 50 0.483
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate.
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logistic regression analysis in the total study population,
female sex was associated with a 2-fold higher risk of LA
dilatation independent of a significant association with
higher pulse pressure (Table 3). Adding 24 h mean BP to
the model did not change the results.
Concentric LV geometry
When concentric remodeling and concentric LVH was
considered together as concentric LV geometry, the preva-
lence of LA dilatation did not differ between groups of par-
ticipants with and without concentric LV geometry (69% vs.
67%, p Z 0.725). In univariable logistic regression analyses,
concentric LV geometry wasmore prevalent inmen (OR 1.74
[95% CI 1.08e2.79], pZ 0.022) and associatedwith presence
of antihypertensive treatment (OR 2.49 [95% CI 1.48e4.19],
p Z 0.001), higher pulse pressure (OR 1.04 [95% CI
1.01e1.06]) and higher age (OR 1.05 [95% CI 1.02e1.08], both
p < 0.001). When these covariables were included in a
multivariable model, prevalent concentric LV geometry was
significantly associated only with higher age (Table 3). Add-
ing 24 h mean BP to the model did not change the results.
In men, concentric LV geometry was associated with
use of antihypertensive treatment (OR 3.52 [95% CI
1.66e7.46], p Z 0.001), but not with prevalent hyperten-
sion (OR 1.8 [95% CI 0.74e4.37], p Z 0.194). In women,
concentric LV geometry was associated with presence of
hypertension (OR 2.91 [95% CI 1.32e6.43], p Z 0.008), but
not with use of antihypertensive treatment (OR 1.75 [95%
CI 0.82e3.72], p Z 0.146).
Abnormal LV geometry
Abnormal LV geometry was present in 25% of the study
participants andmore common inmen than inwomen (30%
vs. 21%, p Z 0.011) (Table 2 and Fig. 1). Men had a higher
prevalence of LVH and higher prevalence of concentric LV
geometry thanwomen (both pZ 0.021) (Table 2). Men had
more concentric LVH (p Z 0.016) than women, but the
prevalence of concentric LV remodeling (p Z 0.360) and
eccentric LVH (p Z 0.325) did not differ by sex (Fig. 1). In
univariable logistic regression analyses, male sex (OR 1.64
[95% CI 1.12e2.41], p Z 0.011), higher pulse pressure (OR
1.04 [95% CI 1.02e1.06], p < 0.001), higher BMI (OR 1.09
[95% CI 1.01e1.14], p < 0.001), higher age (OR 1.05 [95% CI
1.02e1.07], p < 0.001) and use of antihypertensive treat-
ment (OR 1.83 [95% CI 1.16e2.86], p Z 0.009) were all
associated with having abnormal LV geometry, while no
significant association was found with diabetes mellitus
(p Z 0.12). In multivariable logistic regression analysis,
based on the univariable analyses, male sex was associated
with a 2-fold higher risk of abnormal LV geometry, inde-
pendent of significant associations with higher pulse pres-
sure, BMI and age (Table 3). Adding 24 h mean BP to the
model did not change the results.
Any subclinical cardiac disease
When presence of LA dilatation or abnormal LV geometry
was considered together, subclinical cardiac disease was
found in the majority of the participants (71%). The overall
Table 2 Echocardiographic characteristics of overweight and obese women and men.
Variable All (n Z 581) Women (n Z 351) Men (n Z 230) p-value
IVS thickness end-diastole (cm) 1.1  0.2 1.0  0.2 1.2  0.2 <0.001
LV diameter end-diastole (cm) 5.0  0.5 4.8  0.4 5.2  0.5 <0.001
PW thickness end-diastole (cm) 0.8  0.2 0.8  0.1 0.9  0.2 <0.001
LA volume index (ml/m2) 19.9  5.8 20.0  5.6 19.7  6.0 0.520
LA dilatation (%) 67 74 56 <0.001
LV mass index (g/m2.7) 39.3  9.0 37.6  7.9 41.8  9.9 <0.001
LV hypertrophy (%) 16 13 20 0.021
Relative wall thickness (ratio) 0.34  0.08 0.33  0.07 0.35  0.08 <0.001
Concentric LV geometry (%) 14 11 18 0.021
Abnormal LV geometry (%) 25 21 30 0.011
Any subclinical cardiac disease (%) 71 77 62 <0.001
Mitral regurgitation (%) 41 40 42 0.604
Grade 1 (%) 38 36 40 0.371
Grade 2 (%) 3 4 2 0.305
IVS, interventricular septum; LV, left ventricular; PW, posterior wall; LA, left atrial; LV, left ventricular.
Table 3 Associations of LA dilatation, concentric LV geometry, abnormal LV geometry and any subclinical cardiac disease in the total study
population in multivariable logistic regression analyses.
Covariables LA dilatation Concentric LV geometry Abnormal LV geometry Any subclinical cardiac disease
Female sex 2.42 (1.67e3.49)y 0.62 (0.38e1.03) 0.55 (0.36e0.84)* 2.19 (1.48e3.22)y
PP (mmHg) 1.02 (1.00e1.04)* 1.02 (1.00e1.04) 1.02 (1.00e1.04)* 1.03 (1.01e1.05)y
BMI (kg/m2) NA NA 1.12 (1.06e1.17)y 1.06 1.01e1.12)*
Age (years) NA 1.04 (1.00e1.07)* 1.04 (1.02e1.07)* NA
Antihypertensive treatment NA 1.68 (0.94e2.98) 1.03 (0.61e1.73) NA
LA, left atrial; LV, left ventricular; PP, pulse pressure; BMI, body mass index; NA, not applicable.*P < 0.05, yP  0.001.
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prevalence of subclinical cardiac disease was higher in
women than in men (77% vs. 62%, p < 0.001) (Table 2). In
univariable logistic regression analyses, female sex (OR 2.03
[95% CI 1.41e2.93], p < 0.001), higher pulse pressure (OR
1.03 [95% CI 1.01e1.04], p Z 0.006) and higher BMI (OR
1.06 [95% CI 1.01e1.11], p Z 0.017) were all significantly
associated with having any subclinical cardiac disease,
while no associations were found with age, diabetes mel-
litus or antihypertensive treatment (all p > 0.11). Multi-
variable logistic regression analysis identified that female
sex was associated with a 2-fold higher risk of having any
subclinical cardiac disease, independent of significant as-
sociations with higher pulse pressure and BMI (Table 3).
Adding 24 h mean BP to the model did not change the
results. When excluding the participants with diabetes
mellitus in a secondary analysis, female sex remained
associated with 2-fold higher risk of any subclinical cardiac
disease, independent of significant association with higher
pulse pressure, while the previous association with higher
BMI became insignificant (data not shown).
In sex-specific analyses, systolic blood pressure, pulse
pressure and HbA1c were identified as covariables of
prevalent subclinical cardiac disease in univariable logistic
regression analyses in women, while only pulse pressure
retained the independent association in multivariable
analysis. The results did not change when hypertension
was forced into the model (Table 4). In men, average 24-h
pulse pressure and fat-free mass were independent cova-
riables of subclinical cardiac disease both in univariable
and multivariable analyses, and the results did not change
when antihypertensive treatment was forced into the
model (Table 4).
Discussion
Sex, obesity and LA dilatation
Previous studies in hypertension have identified higher
BMI as an important, blood pressure independent covari-
able of LA dilatation [1,5]. Furthermore, a higher preva-
lence of LA dilatation in women than men has been
reported in elderly hypertensive patients with LVH [21]. In
a population based German cohort, Stritzke et al. found
that obesity was the most important factor associated with
increasing LA size with aging. In that population, LA
Figure 1 Left ventricular geometry in overweight and obese women and men.
Table 4 Associations of subclinical cardiac disease in sex-specific uni- and multivariable logistic regression analyses.
Covariables Women Men
Univariable Multivariable Univariable Multivariable
Pulse pressure (mmHg) 1.04 (1.02e1.07)* 1.06 (1.00e1.16)* 1.02 (0.99e1.05) NA
24 h pulse pressure (mmHg) 1.03 (0.99e1.06) NA 1.04 (1.01e1.08)* 1.04 (1.00e1.07)*
Clinic systolic blood pressure (mmHg) 1.02 (1.01e1.04)* 0.99 (0.95e1.03) 1.02 (1.00e1.04) NA
Hypertension 1.16 (0.68e1.96) 0.86 (0.45e1.64) 1.49 (0.81e2.71) NA
Antihypertensive treatment 1.51 (0.74e3.06) NA 1.09 (0.56e2.10) 1.04 (0.51e2.12)
HbA1c (%) 2.08 (1.11e3.88)* 1.71 (0.87e3.39) 1.04 (0.65e1.67) NA
Diabetes mellitus 1.60 (0.64e3.98) NA 1.40 (0.47e4.17) NA
Fat-free mass (kg) 1.00 (0.96e1.04) NA 1.04 (1.01e1.08)* 1.04 (1.00e1.08)*
Age (years) 1.02 (0.99e1.05) NA 1.01 (0.98e1.04) NA
*P < 0.05.
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dilation was equally prevalent among normotensive obese
women and men, but twice as prevalent in women when
hypertension was co-present [10]. The current study ex-
pands these observations by demonstrating that subclini-
cal cardiac disease is highly prevalent also in middle-aged
overweight and obese subjects without known cardio-
vascular disease, found in 71%. Furthermore, LA dilatation
was the most prevalent type of subclinical cardiac disease,
and particularly common in women.
It is well demonstrated that presence of LA dilatation
carries a higher risk for incident clinical cardiovascular
events including atrial fibrillation [1,5]. As proof of
concept, Proietti et al. noted that LA dilatation was
particularly common in elderly women with atrial fibril-
lation, and also associated with higher cardiovascular
mortality in these women [22]. Taken together, these
findings suggest that women are at particular risk of
developing LA dilatation and associated cardiovascular
events when obesity and hypertension are co-present.
Sex, obesity and LV geometry
In a previous study, de Simone et al. found that in hyper-
tension, obese women had a 3-fold higher prevalence of
LVH compared to normal weight women, while obese men
had a 2-fold increased prevalence LVH compared to their
normal weight counterparts [23]. The Strong Heart Study
also reported that obesity had a greater adverse effect on
LV geometry in women than in men, even after adjustment
for important factors like age, systolic blood pressure and
hypertension [9]. Furthermore, obesity-related factors like
waist-to-hip ratio and adipose mass were particularly
associated with higher LV mass in women in the Strong
Heart study [9]. In contrast, the present study found
abnormal LV geometry, including concentric LV geometry
and LV hypertrophy, to be more prevalent in men, and no
association between abnormal LV geometry and obesity
related measures was demonstrated in either sex. A
possible explanation for the diverging findings may be that
a disproportionally high prevalence of women had com-
bined obesity and hypertension and associated LV hyper-
trophy in the study by de Simone et al. [26], while, in the
present study population, women and men were equally
obese, but combined hypertension and obesity was more
prevalent in men. The impact of combined obesity and
hypertension on LVH has been well demonstrated by
Mancusi et al. who found the prevalence of LVH to increase
exponentially with increasing BMI, being seven times
more prevalent in obese compared to normal weight
subjects with hypertension in the Campania Salute
Network registry [24].
Increased pulse pressure, reflecting increased arterial
stiffness, has been associated with higher risk of cardio-
vascular events in several studies [25,26]. The present re-
sults add to this by demonstrating that higher pulse
pressure was consistently associated with presence of
subclinical cardiac disease in the present study, whether
assessed by LA dilatation or abnormal LV geometry. Higher
pulse pressure is a marker of hypertensive target organ
damage, and particularly prevalent in women and in older
age [5,27]. Mancusi et al. found that high pulse pressure
>60 mmHg, was more prevalent in women and in patients
with diabetes mellitus, and a predictor of cardiovascular
events independent of presence of hypertension associ-
ated target organ damage like carotid plaque and LVH [27].
Compared to the present study population, the partici-
pants in these previous studies were older and had higher
prevalences of diabetes mellitus [25e27]. Thus, the pre-
sent findings add to previous knowledge by demonstrating
the important and independent association of higher pulse
pressure with prevalent subclinical cardiac disease, also in
overweight and obese middle-aged subjects free from
clinical cardiovascular disease with a low prevalence of
diabetes mellitus. Furthermore, our results show that
partly different risk factors for presence of subclinical
cardiac disease were identified in obese women and men.
This underscores the importance of using a sex-specific
approach when evaluating the cardiovascular risk factor
profile [28].
Study limitations
The FATCOR study was cross-sectional in design, thus
cause-effect relationships could not be established. The
FATCOR population was free of known cardiovascular
disease, and generalization of the results to less selective
obese cohorts should be done with caution. As the FATCOR
participants were included by general practitioners with a
particular focus on overweight and obesity, it is possible
that the participants focused more on improving their
health and lifestyle than an unselected population, and
that this influenced our findings. Body composition was
measured with foot-to-foot bioelectrical impedance. This
method can underestimate fat-free mass in obese subjects,
and the measurement of body fat may be influenced by sex
and age [29,30]. We cannot exclude that this may have
influenced findings in the present study population.
However, women and men had comparable age.
Conclusions
In the FATCOR population, including overweight and obese
subjects without known cardiovascular disease, the ma-
jority of participants had prevalent subclinical cardiac
disease, which may contribute to explain the impaired
prognosis observed in obesity. Women had a higher
prevalence of subclinical cardiac disease than men. LA
dilatation was particularly common among women, while
abnormal LV geometry was more prevalent among men.
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